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ABSTRACT 
Swedish registers have for decades successfully been used for medical research, enabling long-term 
follow-up of large patient cohorts using observational designs. With a tax funded health care system 
and the use of a personal identity number as a unique identifier, together with national health 
registers as well as national demographic registers, we have to a relatively low cost the possibility to 
answer an abundance of research questions in a real-world setting. 
This thesis describes how the Swedish Rheumatology Quality register (SRQ) can be enriched with 
national register data for estimating disease occurrence, assessment of health care resource use and 
work loss, and for potentiating randomized controlled trials (RCTs) conducted within the register 
framework. More specifically, by using the SRQ that collects disease specific data on patients with 
rheumatic diseases in routine clinical care together with objectively assessed data from national 
registers we could in a large sample of patients with rheumatoid arthritis (RA) estimate the incidence 
and burden of RA. Furthermore, with a randomized pragmatic clinical trial included in the register 
framework, we could provide information on health economic outcomes regarding a common clinical 
question in early RA, whether to continue treatment by adding an expensive biologic alternative or to 
continue with a conventional combination treatment strategy after insufficient response to 
methotrexate. 
We found an overall incidence of RA in Sweden on a par with previous local but detailed studies (41 
per 100,000; paper I), with a substantial variation across age and sex. We observed that the incidence 
of RA peaked in the 7th decade in life in both sexes, and that the incidence in women was more than 
twice the incidence observed in men. Furthermore, we observed lower incidence estimates in 
individuals with higher education level and in densely population areas. With respect to burden of 
disease, we used general population comparators individually matched to register-identified subjects 
with RA and estimated the annual societal cost in prevalent as well as monthly societal cost in newly 
diagnosed patients to 2-3 times higher than in the general population (paper II). 
The randomized Swefot trial compared the addition of the biologic drug infliximab versus conventional 
combination therapy in patients with early RA who had failed initial methotrexate monotherapy. With 
the Swefot trial included in the SRQ, we could for the first time in a randomized register trial setting 
analyze work loss and cost-effectiveness for a strategy adding a biologic alternative as compared to 
conventional combination therapy in methotrexate-refractory early RA. 
We observed a substantial decrease in mean monthly work loss days in both treatment alternatives, 
with a reduction of 3 times to double that in the general population from randomization to 21 months 
of follow-up, but no difference between the strategies could be detected (paper III). This remaining 
gap to the general population indicates a need for earlier diagnosis as well as for more effective 
treatment strategies of RA. In the cost-effectiveness analysis we observed similar effects between the 
strategies over 21 months, while the infliximab strategy incurred higher costs (paper IV), suggesting 
that an attempt with conventional combination therapy appears reasonable before starting infliximab 
treatment in methotrexate-refractory early RA, both from a clinical and economic perspective. 
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1 INTRODUCTION 
For decades, Swedish registers have successfully been used for medical research, enabling long-term 
follow-up of large patient cohorts using observational designs. For example, the early established 
Swedish Cancer register has frequently been used to study cancer-related research questions,1 and 
has, through the personal identity number, been enriched with data on hospital admissions for 
studying the risk of cancer among patients with a specific medical condition. Other early examples of 
using register-based designs in health-related research are found from the Scandinavian Simvastatin 
Survival Study2 and the prospective-controlled Swedish Obese Subjects study3 linked to national 
register data for studies on mortality, cancer, and hospitalizations.4,5 
More recently, research databases have been established including several data sources using clinical 
quality registers enriched through register linkage with outcomes such as mortality, cancer, and work 
loss from national registers.6-8 Hereby a high granularity regarding clinical information can be obtained 
from the quality registers, while still exploiting the strengths associated with national registers. 
Moreover, while quality registers can provide much valuable data on their own, the true potential for 
both research and health care improvement may be in the combination through register-linkage and 
extensions where randomization occurs within the quality register framework.9,10 However, enriched 
quality register data create both new possibilities and potential problems for evaluation of 
effectiveness, safety, and health economic outcomes. 
The four studies included in this thesis provide examples of how register-linkage can be used for 
estimating disease incidence, testing the robustness of register-based identification of disease, 
assessment of health care resource use and work loss, and for potentiating randomized controlled 
trials (RCTs) conducted within clinical quality registers. 
Apart from being examples of how to use and enrich quality registers, the studies are also of scientific 
interest in their own regard, providing information regarding disease incidence and the burden of 
disease on an unprecedented scale within the field of rheumatoid arthritis (RA) (papers I and II). The 
register-enriched RCT enables analysis on whether differences in radiological outcomes translate into 
actual changes in work loss (paper III), something that is commonly claimed and used as motivation 
for the high cost of biologic drugs in RA.11-16 Finally, the register-enriched RCT can also be used for cost-
effectiveness analysis of biologic versus conventional combination treatment (paper IV), adding 
important data to the ongoing discussion whether expensive biologic alternatives are good value for 
money as second line treatment compared to considerably cheaper non-biologic alternatives.17-20 
The introduction section is aimed to introduce the concepts needed for interpretation of the studies 
included in this thesis, and starts with a brief overview of the register linkage procedure and the 
personal identity number, followed by an introduction to epidemiological concepts of study designs 
and analyses, concepts of health economic analysis, description of RA and how the register-based 
methodology in this thesis add to the existing knowledge, and ends with ethical considerations. 
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1.1 REGISTER-BASED RESEARCH IN SWEDEN 
The setting in Sweden, with a tax funded health care system and drugs that are provided free of charge 
above a threshold (2200 SEK in year 2014; www.tlv.se), and most importantly from a data linkage 
perspective, a personal identity number for all Swedish residents, makes Sweden an attractive 
environment for register-based research. With the virtually complete inpatient register of hospital 
discharges, together with the non-primary outpatient part of the National Patient Register, disease 
conditions and events of many study subjects are accessible, while dispensed prescription drugs for 
any indication are available from the Prescribed Drug Register. These national health registers, held at 
the National Board of Health and Welfare, are important data sources in health-related research in 
Sweden. 
In addition to the national health registers, there are several quality of care registers in Sweden that 
collect data on a specific disease or intervention. These registers are usually established within the 
medical profession, and historically by enthusiasts, since it usually requires a huge effort in the start-
up phase. The purpose of these registers is to monitor and improve health care, in some cases to 
provide the treating physician with individual decision support, and to conduct research. In 2014, 81 
registers were qualified, by the National Board of Quality of Care Registers in Sweden, to be of 
sufficient quality to receive a certificate of quality register and to receive funding from the government 
for improvement and to further increase the quality of the register (http://www.kvalitetsregister.se/). 
The Swedish Rheumatology Quality Register (SRQ), including the biologics register ARTIS (Anti-
Rheumatic Therapies in Sweden), is a quality of care register that collects disease specific data on 
patients with rheumatic diseases in daily clinical practice.6 For the data used in this thesis, we have, 
through the personal identity number, linked the SRQ to national health registers as well as to other 
quality of care registers, and to the registers at the Social Insurance Agency. By the data enrichment 
procedure of the SRQ we have at a low cost established a powerful enriched clinical care register 
database where we have the possibility to answer an abundance of research questions, over a long 
time period with virtually complete follow-up, and in a real-world setting. 
1.2 THE SWEDISH PERSONAL IDENTITY NUMBER 
All persons who are registered in Sweden are assigned a 10 digit personal identity number 
administrated by the Swedish Tax Agency.21 The structure of the personal identity number includes 
data on birth and sex, where the first six numbers describes date of birth (YYMMDD), and is followed 
by a three-digit birth number, where the third digit specifies the sex of the individual (odd number 
indicating male and even number indicating female). The tenth and final digit is a control number 
indicating if the date of birth and the three digit number are correct. From this structure, the total 
number of possible unique personal identity numbers are 500 male and 499 female combinations for 
the same date.22 
The system of personal identity number was established in 1947, with the control number added in 
1967.22 This system is fundamental in the Swedish society where many of the rights and obligations as 
a Swedish resident hinge upon identification in registers and by authorities, and is also of great 
importance in medical research. Although the personal identity number is unique, there are situations 
where numbers have been reused or have been corrected, resulting in that the same personal identity 
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number has been assigned to more than one person, or that more than one number have been 
assigned to the same person, respectively. Reuse of personal identity numbers is rare, but may be 
necessary due to the limited number of unique combinations for the same date. In the 1950s and 
1960s, Sweden had many immigrants that received 1st of January or 1st of July as date of birth, and this 
explains why reuse of numbers during this period is more common. The most common reasons for 
changing the personal identity number is incorrect date of birth or incorrect sex among immigrants or 
newborns. Other more uncommon situations for changing the personal identity number is adults 
changing sex, and in individuals requiring protected identity. 
An estimated 13,500,000 personal identity numbers have been provided from 1969 until January 
2008, whereof 15,887 numbers were reused, and 75,638 individuals had received a new personal 
identity number, including 26,265 out of 7,938,077 individuals born in Sweden (0.33%).22 Although the 
number of reused and changed personal identity numbers are few compared to the total number 
assigned, the researcher has to be aware of the potential problem and take this into consideration 
when working with register data linkages. 
1.3 OCCURRENCE OF DISEASE 
In epidemiology, there are two fundamental measures to describe the occurrence of disease, 
incidence (proportion or rate) and prevalence (proportion).23 The incidence proportion, or sometimes 
just incidence, is a measure of risk for developing a condition within a period of time, while incidence 
rate includes the time at risk for the individual study subjects. The incidence proportion is defined as 
the number of new cases during a time period, divided by the total number of study participants 
initially at risk. In contrast, the denominator in the incidence rate measure is the sum of person-years, 
or any other time unit, which the total number of study participants initially at risk contribute to the 
cohort study. If all study subjects can be followed throughout the study period, the incidence 
proportion is equal to the incidence rate. Unlike the prevalence measure, which describes the spread 
of a disease as a proportion of cases in the population at a given point in time (or during a given period 
in time), the incidence describes the occurrence of new cases.24 
1.4 COHORT STUDIES 
A cohort study is a type of observational study design where study subjects are divided into groups 
based on exposure and are followed over time, with an aim of measuring the occurrence of one or 
several outcomes during the follow-up period, and to compare these occurrence rates between 
groups.23 Compared to RCTs, cohort studies typically have long follow-up time and high generalizability 
by including a representative sample of the source population. However, they may suffer from 
methodological issues, which make it difficult to estimate causal effects for a specific intervention or 
other exposure. A major methodological problem is that patients may be selected by certain known 
or unknown characteristics to a specific treatment, resulting in selection bias. Other problems may be 
challenges to define exposure status, and the high cost associated with collecting all data needed to 
have enough statistical power. However, the latter is not much of an issue when using national 
population-based registers available for example in Sweden. 
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1.4.1 Analysis 
Cohort studies often involve research questions with time to a specific event, such as time to death, 
time to a specific disease, or time to treatment discontinuation, and study subjects may drop out of 
the study before the end of follow-up. With different time at risk for study subjects, occurrence of 
disease can be measured by the incidence rate. To include time at risk in the analysis, the association 
between exposure status and the outcome or event is usually evaluated using survival analysis, where 
the Cox proportional hazard regression often is used, enabling adjustment for potential confounders 
and investigate effect modification.25 
1.4.2 Matching 
Matching of unexposed comparator subjects to exposed study subjects on certain characteristics that 
may affect both the exposure and the outcome is one way to deal with confounding in cohort studies, 
since the potential association between exposure status and matching factors at baseline are 
prevented.26 One advantage for matching on a set of characteristics compared to adjusting for the 
same characteristics in a cohort study design without matching, is that potential interactions among 
the matching factors are also included in the matched design. This allows for estimation of an overall 
effect, whereas controlling for several interactions may complicate the interpretation of results. In 
contrast, results from a matched design of unexposed to exposed study subjects may be easily 
presented, since the cohorts are followed side by side over time. However, although potential 
confounding for matching factors at start of follow-up are reduced in a matched cohort design, these 
characteristics may still need to be controlled for in the analysis if the exposure and the matching 
factors affect the time at risk, or if there are additional confounders, even when adjusting for the 
additional confounders.27 
1.5 RANDOMIZED CONTROLLED TRIALS 
The randomized controlled trial is the gold standard design for measuring causal effects, meaning that 
since everything else is equal, there is a causal effect of the intervention if the outcome differs 
between groups to which subjects have been allocated at random. Subjects are randomly allocated to 
receive an intervention (or placebo), and are thereafter followed over time. With the randomization 
procedure, both known and unknown confounders are ideally spread out and balanced in the 
treatment groups, with reduced potential for biased estimates from patient characteristics that may 
have an effect on the outcome. Limitations of RCTs, with its experimental nature of the design, are 
that trials commonly include a selected group of participants due to strict inclusion and exclusion 
criteria, have a limited follow-up time, and are expensive to conduct. Thus, RCTs typically have high 
internal validity (unbiased and valid estimates of the treatment effect on the outcome), while the 
external validity (the generalizability) of the estimated effect might be limited. 
There are different approaches to analyze RCT data, where the intention-to-treat (ITT) principle is the 
dominant strategy in the interpretation of RCTs.28 Under the ITT, all patients allocated to a treatment 
are followed in that treatment group regardless of protocol breach. For example, in the analysis 
subjects remain in the treatment group to which they were allocated regardless whether the patient 
never received the allocated treatment, mistakenly received the alternative intervention, or did not 
adhere to the intended treatment. Using the ITT approach, characteristics other than the pure 
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biological effect that may influence the efficacy of the intervention are included in the analysis. Such 
characteristics may be the ability to administer the drug, drug adherence of the patients, as well as 
other measured or unmeasured characteristics among the patients. 
Other approaches to analyze RCT data are per-protocol analysis, where study subjects that completed 
the trial according to protocol are included, and modified ITT,29 where study subjects with some 
deviations from the study protocol are excluded. 
In Figure 1 the rationale behind the ITT approach is presented in a directed acyclic graph.30 If data from 
an RCT is analyzed by the ITT method, the effect of the allocated treatment R on the outcome Y is 
measured, and the path from A → Y through the unmeasured confounding U is blocked according to 
graph theory in directed acyclic graph (A is a collider). If instead using per-protocol analysis, the 
treatment effect of drug A on the outcome Y is measured, which may be biased by the potential 
unmeasured confounding U since the path A ← U → Y is unblocked. 
If no confounding, selection bias or measurement bias for the randomly assigned treatment R exists, 
the association between R and the outcome Y can be interpreted as the causal effect of R on Y. 
However, using the ITT approach and, as in most situations in randomized trials, with patients not 
adherent to the allocated treatment, potential misclassification bias is introduced. While, as noted, in 
per-protocol analysis potential unmeasured confounding may instead result in a biased estimate of 
the treatment effect. 
 
Figure 1 Directed acyclic graph of a randomized trial 
R: Randomly allocated treatment; A: Adherence to the assigned treatment;  
U: Unmeasured confounding; Y: The outcome of interest 
 
1.6 REGISTER-ENRICHED RANDOMIZED CONTROLLED TRIALS 
The combination of randomization and observational register data, with an RCT conducted within the 
register-enriched framework, has the potential of using the generalizability of “real world data” that 
has been recorded in daily clinical practice along with properties of randomization such as a reduced 
risk of selection bias. 
In more detail, by combining real-world data with a randomization procedure in the quality of care 
register, the long follow-up, many different outcomes, and clinically relevant comparisons between 
treatments from the register data are combined with the possibilities of estimating causal effects from 
the RCT. The features of including clinically relevant interventions, inclusion of a diverse population of 
participants recruited in a real-world clinical setting, and data collection on several different outcomes, 
refer to the term pragmatic clinical trial or practical trials.31 Finally, since the clinical data are entered 
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into the quality of care register in routine practice, this design allows for long-term follow-up at a low 
cost. 
1.7 COST AND COST-EFFECTIVENESS STUDIES 
Economic assessments of the treatment of disease evaluate the economic value of therapeutic 
interventions with an overall aim to maximize health. A common study design in economic 
assessments captures self-reported data on costs from questionnaires. While this design enables data 
collection on a detailed level, questionnaires are commonly associated with both non-response and 
recall bias. By instead using a register-enriched database with objectively assessed data on health care 
and work loss, the weaknesses inherent in using questionnaires may be avoided, but with the loss of 
collecting all potential cost components. 
While studies of burden of disease, or cost of illness, assess the health care use and/or work loss, cost-
effectiveness studies combine the costs incurred by the new intervention and the health related 
quality of life gained from it, compared to another intervention. The comparison intervention may for 
example be standard of care or no intervention at all. The results are presented as incremental costs 
and effects between the treatment groups, and usually in an incremental cost-effectiveness ratio 
(ICER), which is defined as the difference in costs divided by the difference in effects between 
treatment alternatives. 
1.7.1 Costs 
Costs are generally divided into three categories, health care costs, productivity losses, and intangible 
cost. 
Health care costs, sometimes referred to as direct costs, are all costs associated with the health care 
used for having the intervention in question. For valuing productivity losses, sometimes referred to as 
indirect costs, two methods are often used, the human capital approach and the friction cost method, 
where the former is heavily dominating cost of illness studies in RA. Finally, intangible costs refer to 
the suffering incurred by the disease and the interventions needed, and may be more difficult to 
quantify than direct and indirect costs. 
1.7.1.1 Human capital approach 
The human capital approach values productivity losses by using the value of an individual’s future 
earnings. The market value of lost productivity associated with illness is therefore an individual’s 
reduced production as compared with if the same individual would continue to be in full health. The 
reduced production is estimated using gross earnings with taxes included, and hence, valued to the 
actual amount the employer pays for the production delivered.32 
There are a number of limitations using the human capital approach. Criticisms have been raised 
against the assumption that, even if the unemployment rate would be high, a worker cannot be 
replaced. Further, the value of future production may not reflect the gross earnings (e.g. housewives), 
and leisure time is not valued as it would be in general welfare economics.32 
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1.7.1.2 Friction cost method 
The friction cost method uses the same underlying assumption as the human capital method, that 
future production is valued using the individual’s future earnings. The difference compared to the 
human capital approach is the assumption that the worker can be replaced after a period of time, 
referred to as the friction time, until the absent worker returns or is replaced.33  
In the short-term, the human capital and the friction cost method result in similar estimates of 
productivity losses. However, in the long-term, lower cost estimates would be obtained with the 
friction cost method. 
One concern with the friction cost method is that illness and premature death would result in reduced 
unemployment rates in the overall society. Furthermore, it has been argued that, for consistency, the 
friction cost method should also be used to estimate direct costs, resulting in unrealistic health care 
cost estimates.34 After the friction period, the price of labor is set to close to zero, which implies a 
substantially reduced health care cost since the labor cost is a major part of the value added in a health 
care program.34 Finally, estimating the length of a friction period may be challenging, as it is likely to 
differ according to characteristics such as employment position, educational level, and the situation 
on the labor market.35 
1.7.2 Perspectives 
Costs and benefits that are relevant to include in the analysis depend on which perspective being used. 
Common perspectives used in cost-effectiveness analysis are the individual, health care, and societal 
perspectives. For example, from the health care perspective, costs of drugs and resource use in the 
therapy delivered would be relevant, while productivity losses are not borne by the hospital and 
should not be included. However, to identify the most efficient use of health care, and since 
productivity losses are part of the social resources and paid for by taxes, it has strongly been 
recommended to include productivity losses and to use the societal perspective in cost-effectiveness 
analysis.36,37 
1.7.3 Health-related quality of life 
Cost-utility analysis is one type of cost-effectiveness analysis where the effect is measured as quality 
adjusted life-years (QALY) gained. Utility is a valuation of health-related quality of life in states where 
0 indicates dead and 1 indicates full health. A QALY is the product of the utility value of a specific health 
state and the time spent in the health state. One common instrument to measure utility in cost-utility 
analysis of RA is the EuroQol 5-Dimensions (EQ-5D) instrument.20,38,39 The EQ-5D comprises five 
questions regarding mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, with 
three alternative responses for each (an updated version with five alternatives is under development; 
http://www.euroqol.org/). 
The 243 different health states in the three-level EQ-5D questionnaire (35=243 possible combinations) 
may be converted to a single country specific index value.40 Cost-utility analyses on Swedish data often 
use index values from the UK, and sometimes from the US. However, experience-based value sets for 
EQ-5D health states in Sweden have recently been published, but may be investigated in more detail 
before implementation.41 
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As with the Swedish preference set, both the UK and the US preference sets have used the time trade-
off (TTO) method in deriving index values to each health state. The TTO method compares the time in 
a specific health state to the time with full health. Time in the current health state is varied until the 
respondent is indifferent between the alternatives. The utility score for the current health state is then 
the time with full health divided by the time in the current health state. For example, a patient 
indicates that ten years of living would be required in his or her current health state to be equivalent 
of three years of living with full health. The utility in this health state would then be 0.3 (3/10). 
In longitudinal data where several measurements over time are available, accumulated QALYs during 
follow-up are often used. Accumulated QALYs are calculated as the area under the utility curve, with 
utility on the y-axis and time on the x-axis. 
Major advantages of the QALY approach, in contrast to many other effect measures, are that the QALY 
measure captures changes both in morbidity and mortality, and may be compared among all patients 
and between different diseases, interventions and health care programs. 
One limitation with the QALY measure is that all QALYs are considered to have the same value. For 
example, few patients with a large increase in health-related quality of life may result in similar 
estimates as when many patients have a small increase. Some argue that a high QALY change among 
few patients that may be life-saving, should be given more weight as compared to a small increase 
among many patients,32 as may often be the case in chronic inflammatory diseases such as RA. 
Furthermore, QALYs do not take into account when in life the change of health-related quality of life 
takes place. 
1.7.4 Discounting 
Discounting in health economic assessment is a method used to adjust for future costs and benefits 
to the present value. The concept of discounting is that receiving something with a value today has a 
greater value than to receive the same thing in the future. 
National pricing and reimbursement agencies usually recommend discounting of cost and health 
effects at an annual rate of 3% or 5% in the main analysis, and up to 10% in sensitivity analysis, and 
also without discounting of health effects.42 While there is an agreement among health economists 
that future costs should be discounted, there is some disagreement regarding which discount rate to 
use for future benefits, or whether to discount future benefits at all. Some have argued that a year of 
life is the same whenever it occurs in time, and health effects should for that reason not be discounted. 
However, much of the literature indicates that individuals place greater weight on benefits that occur 
soon in time, as compared to delayed benefits, suggesting that future benefits should be discounted 
in the analysis.43 The Swedish national reimbursement agency, the Dental and Pharmaceutical Benefits 
Board (www.tlv.se), recommends discounting of both costs and effects to an annual rate of 3%, and 
to conduct sensitivity analysis with discount rates of 0% and 5%.36 
1.7.5 Incremental cost-effectiveness ratio (ICER) 
The ICER combines the costs and effects for one intervention compared to another intervention (often 
the standard care) and is used in health economics for supporting decision making regarding health 
interventions. The ICER can be presented in the cost-effectiveness plane consisting of four quadrants, 
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quadrants I-IV in a clockwise order starting in the upper right quadrant, with the plotted difference in 
costs (y-axis) against the difference in effects (x-axis) between treatment groups (Figure 2).44 In 
quadrant I the new treatment is more effective but also more costly, in quadrant II the new treatment 
dominates with lower costs and better effect, results in quadrant III indicates that the new treatment 
is less costly but also less effective, and in quadrant IV the standard treatment dominates as the new 
treatment is more costly and less effective. The willingness to pay threshold, the monetary value per 
unit of effect that would be acceptable and considered cost-effective, is also easily presented in the 
cost-effectiveness plane through a line with where the slope represents the threshold. 
 
Figure 2 The cost-effectiveness plane with an imagined willingness to pay threshold (dotted line). The white 
area illustrates acceptance of new treatment, where increased costs for the gained effect may be acceptable 
(upper right quadrant), new treatment dominates (less costly and more effective; lower right quadrant), or 
may be acceptable (less effective but also less costly; lower left quadrant). 
1.8 RHEUMATOID ARTHRITIS (RA) 
RA is a chronic disease characterized by systemic inflammation, joint destruction, and presence of 
autoantibodies, and if not controlled, results in disability, reduced quality of life, and higher risk of 
cardiovascular as well as other comorbidities.45 
1.8.1 Epidemiology 
Around 0.5-1% of the western population are living with RA,46 and around 50,000 individuals have RA 
in Sweden.47 The annual rate of new cases is 20-50 per 100,000, but prevalence and incidence 
estimates differ considerably depending on age and sex, since RA onset is more common in older 
individuals and 2-3 times more common in women than men.48 Other risk factors for RA includes 
genetic factors, with a 3-fold increase risk when family history of RA is present,49 and smoking, the 
strongest environmental factor with approximately a 2-fold increased risk for RA.50,51 
With respect to previous incidence estimates of RA, reports have suggested that the incidence has 
declined during the second half of the 20th century, while more recent studies report an increase in 
the last decade. With exception of nationwide incidence studies of RA from Finland,52,53 previous 
reports have based their estimates on up to a few hundred individuals with RA diagnosis verified using 
standard RA classification criteria. Such a study design may provide good incidence estimates of 
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defined RA in that specific study area, but may not be generalizable to physician-diagnosed RA on a 
national level, which would be the “real-life” occurrence of RA. Subgroup analysis in small sample 
studies may also be limited or impossible, and it is unclear whether the incidence of RA varies with 
factors other than age and sex, such as demographic factors and geography. 
1.8.2 Definitions and outcome measurements 
RA is a classification disease where no single clinical test alone can be used to verify a diagnosis. To be 
classified as having RA, the patient has to fulfill a number of different criteria. An often used 
classification tool is the American College of Rheumatology (ACR) criteria from 1987,54 with good 
features to verify established RA, but with limitations in identifying patients early in the disease course. 
An updated version has therefore been developed by the ACR and the European League Against 
Rheumatism (EULAR) organizations, the 2010 ACR/EULAR criteria.55 It has been estimated that the 
updated version identifies similar number of incident RA cases at start of follow-up, as the 1987 ACR 
criteria would have identified after five years of follow-up.56 
Severity of RA is usually categorized based on disease activity with the 28-joint count disease activity 
score (DAS28),57 ranging from 0 to 10 (higher number indicates more disease activity), and is often 
used for treat-to-target approaches in clinical practice (Table 1).58 The DAS28 measure consists of 4 
components: number of swollen joints (0-28), number of tender joints (0-28), erythrocyte 
sedimentation rate (ESR), and the patient-reported general health assessment on a visual analogue 
scale (0-100). 
Other measures of disease severity are the health assessment questionnaire (HAQ), which is a patient-
reported questionnaire, ranging from 0 to 3, assessing the physical function and disability in patients 
with RA.59 Measures of radiological progression of joint destruction using radiographs of patients’ 
hands and feet are also used. One such scoring system when comparing the radiographs is the Van 
der Heijde modification of the Sharp score, ranging from 0 to 448.60 
 
Table 1 Categories of disease activity based on 28-joint count disease activity score (DAS28) 
Disease activity score Disease activity category 
DAS28 < 2.6 Remission 
DAS28 < 3.2 Low disease activity 
3.2 ≤ DAS28 ≤ 5.1 Moderate disease activity 
DAS28 > 5.1 High disease activity 
 
1.8.3 Management and treatment 
Since the late 1990s the treatment of RA has changed dramatically with the introduction of biologic 
drugs, with superior efficacy in treating disease activity compared to non-biologic alternatives.17 
Biologic drugs for treatment of RA refers to large complex protein molecules that, instead of passing 
the cell-membrane as smaller molecules, act outside the cell by blocking components of the immune 
system that have an important role in the inflammation process. A common mechanism for biologics 
in RA is blocking of a chemical activator of inflammation, the tumor necrosis factor (TNF), and such 
drugs are usually referred to as TNF inhibitors (TNFi). In addition to an increased number of new 
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therapeutic options, treat-to-target approaches, early identification of RA onset, and careful 
monitoring of the disease course have improved the management and treatment of RA.61 
The standard recommendation in RA is to initiate non-biological disease-modifying anti-rheumatic 
(DMARD) therapy as early as possible in the disease course. At this stage, adding low dose 
glucocorticoids may also be considered.62 One common strategy is to initiate treatment with 
methotrexate monotherapy. However, only around one third of the patients reach low disease activity 
after 3 months using methotrexate alone.63-65 In patients who do not respond to the first DMARD 
strategy, current recommendations are to consider an alternative or a combination DMARD therapy 
in those patients with absence of poor prognostic factors (such as rheumatoid factor or anti-
citrullinated protein antibodies, radiographic progression, or high disease activity), and to consider 
adding a biologic drug in those who have poor prognostic factors present.62 
The randomized Swefot trial aimed to answer this common clinical question in early RA, that is, which 
strategy, adding a TNFi or further conventional DMARDs, is preferable in patients not achieving low 
disease activity after 3-4 months of methotrexate monotherapy.65,66 The clinical results showed 
superiority of the TNFi strategy after 1 year,65 but with no difference in DAS28 between the strategies 
after 2 years, although a statistically significant difference in radiographic progression was detected 
favoring the TNFi treatment strategy.66 Similar results have been confirmed from other randomized 
trials using a similar study design,64,67 and also in patients with established RA.68 
However, no health economic analysis regarding which strategy to choose has been reported in this 
patient group, neither regarding work loss outcomes nor in a complete cost-effectiveness analysis. 
1.8.4 Consequences and costs 
With the chronic inflammatory and destructive nature of RA, high health care use, work loss, and 
reduced quality of life have been reported in these patients.69-72 Reduced employment alternatives 
and increased productivity losses imply that evaluations of the burden of disease, not only from a 
health care perspective, but from a societal perspective, are crucial in understanding the value of 
interventions in RA. 
Two recent reviews have compiled data from several burden of disease studies in RA, in an attempt to 
compare existing studies despite the different methodological approaches and differences in disease 
severity and comorbidity in study subjects. The most recent review reported a weighted mean annual 
cost per patient with established RA to €4170 in health care costs and €8452 in productivity losses.70 
The other systematic review found that the cost per patient was €21,069 in the US, €13,463 in Europe, 
and €12,893 in Sweden, and that productivity losses constituted less than 50% of the total costs.73 The 
higher cost in the US compared to Europe was due to higher use of biologics. Already in the beginning 
of the biological era, biologic drugs appeared to considerably increase the treatment costs of RA, with 
health care costs mainly driven by drug use instead of hospitalization costs as before the introduction 
of biologics.74 
Cost data often display a skewed distribution where few patients contribute a large proportion of the 
total cost. As a result, in cost of illness analyses, it is important to also understand the underlying cost 
distribution. However, previous cost of illness studies in RA have not based their estimates on 
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nationwide individual level data, and no study has compared these cost estimates to the general 
population in order to understand the additional costs in RA. 
1.9 ETHICAL CONSIDERATIONS 
Ethical approval for the data linkage and for all included studies in this thesis was granted by the 
Regional Ethics Committee, Karolinska Institutet, Stockholm, Sweden. The Swefot study was approved 
by the regional ethics committees of all 15 participating rheumatology units in the trial, and written 
informed consent was given by the participants before inclusion. 
For registration in the SRQ there is a routine of informed consent, and patients have the choice to 
withdraw the consent at any time and for any reason, and all observations would be removed from 
the SRQ. 
Informed consent from study subjects not included in the SRQ is impossible, as these data are 
anonymized and some subjects may already be deceased. In addition, with more than 500,000 
included study subjects in the data linkage, it would also be practically impossible to inform all study 
participants. 
Our opinion that the possibilities of this research project using the SRQ enriched by data from national 
registers outweigh the risk of perceived violation of personal integrity for study subjects, was shared 
by the ethical review board. As further safeguards, the research group only had access to anonymized 
data, and results are only presented on an aggregated level so that individual patients cannot be 
identified. 
This project demonstrates effective research methods at a relatively low cost, methods that could be 
replicated to disease areas other than rheumatology, and on a national level to monitor incidence, 
prevalence, and burden of disease in a way that has not been previously possible, as some of the used 
registers were only recently established. In addition, we hope that the results from this project could 
lead to improvements in health care delivery, and thus, in the future, patients with RA could benefit 
from the study results. 
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2 OBJECTIVES 
The overall aim of this thesis was to describe different ways of using Swedish register data to inform 
evaluations of health care interventions and epidemiologic inquiries, exemplified by using the SRQ 
linked to national registers. 
The specific objectives were: 
1. To combine quality register, national health register, and demographic register data to 
determine the incidence of RA in Sweden (paper I) 
2. To combine quality register, national health register, demographic register, and Social 
Insurance Agency register data to assess the disease burden measured by cost of work loss, 
hospital care, and drug use in prevalent and incident RA (paper II) 
3. To combine randomized controlled trial, quality register, national health register, 
demographic register, and Social Insurance Agency register data to 
a. evaluate the effect on sick leave and disability pension of TNFi+methotrexate versus 
conventional combination treatment in early RA patients not responding to 
methotrexate monotherapy (paper III) 
b. conduct a cost-effectiveness analysis of TNFi+methotrexate versus conventional 
combination therapy from the societal perspective (paper IV) 
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3 MATERIAL AND METHODS 
3.1 SETTINGS 
All Swedish residents have a 10-digit unique personal identity number, administered by the Swedish 
Tax Agency, used to identify residents at authorities and in registers. Using this unique key it is possible 
to merge registers on an individual level to establish a research database which include data from 
different sources. 
In Sweden the health care system is tax funded and offers universal access to all residents, and 
prescription drugs are provided free of charge above a threshold (1800 SEK during the study period, 
2200 SEK in 2014; www.tlv.se). In the case of RA and other inflammatory diseases, patients are 
typically diagnosed and treated by rheumatologists at non-primary outpatient and inpatient care 
facilities, rather than by general practitioners. Care for RA represents a mix of combined outpatient 
and inpatient facilities, with the vast majority of rheumatologists working at hospitals (>90%) rather 
than as private practitioners.75 
3.2 DATA ENRICHMENT OF THE SRQ 
In the data enrichment procedure of the SRQ, the first step was identification of all patients with RA 
in the SRQ, while the National Board of Health and Welfare identified all patients from the National 
Patient Register listing at least one main or contributory diagnosis of RA according to the ICD 
(International Classification of Disease) coding system (Figure 3). For analysis of biologic drug use, 
patients with any biologic drug prescription in the Prescribed Drug Register were also identified. In 
addition, general population comparators were sampled from the demographic registers held at 
Statistics Sweden. Five comparators per RA patient were sampled on an individual level based on age, 
sex, residence, and year. Patients with any RA diagnosis together with their general population 
comparators constituted the study cohort. 
Data on patients in the randomized Swefot trial65 were also collected in the SRQ, as any data collected 
in routine daily clinical care at the rheumatology clinic. The enrolled Swefot patients were thus also 
included in the register-enriched database as subjects in the study cohort, and were also matched to 
general population comparators. 
The study cohort was thereafter merged to the national health registers held by the National Board of 
Health and Welfare, registers at the Social Insurance Agency, as well as other quality of care registers. 
Not all data sources outlined in Figure 3 were included in this thesis. Included data sources are 
described in the next section. 
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Figure 3 The data enrichment procedure of the SRQ. Patients with RA were identified from the SRQ and the NPR. 
In addition, for analyses of biologic drug use, all individuals with prescribed biologics were identified from the 
PDR. After sampling of general population comparators from the Register of Total Population, the study cohort 
was defined. The study cohort was thereafter linked to national registers and to other quality of care registers. 
The SRQ may also be linked to medical files for validation studies and to biobank sample repositories. 
SRQ: Swedish Rheumatology Quality Register; NPR: National Patient Register; PDR: Prescribed Drug Register 
3.3 DATA SOURCES 
All data sources used for the included studies are described in this section, and summarized in Table 
2. 
Table 2 Data used from the different data sources included in the register-enriched database 
Register holder and data source Identification of subjects Data used (years) 
The Swedish Rheumatism Association   
SRQ/ARTIS (including Swefot) Patients with RA 
Clinical data related to RA, HAQ, 
EQ-5D, treatment information 
(1999-2012) 
National Board of Health and Welfare   
National Patient Register 
Patients with main or 
contributory diagnosis for RA 
Health care use (not primary care; 
inpatient: 1971-2012; outpatient: 
2001-2012) 
Prescribed Drug Register - 
Drug prescriptions (not in-hospital 
drug use; July 2005 - 2012) 
Cause of Death Register - Deaths (1956-2012) 
Statistics Sweden   
Register of the Total Population 
Sampling of comparators on age, 
sex, place of residence, and year 
Birth, death, civil status, country 
of birth, migration (1968-2012) 
LISA - Level of education (1990-2012) 
Social Insurance Agency   
Social insurance compensations - 
Compensated days for sick leave 
and disability pension (1994-2012) 
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3.3.1 The Swedish Rheumatology Quality Register (SRQ) 
The SRQ was started in 1995 by the Swedish Rheumatology Society. It followed on regional register 
initiatives,76,77 and developed over time into a harmonized national register. The primary purpose of 
SRQ was to improve the health care and treatment for patients with RA, but with time patients with 
other rheumatic diseases, e.g. ankylosing spondylitis (AS) and psoriatic arthritis (PsA), have also been 
included. In the late 1990’s, when the first biologic drug was approved for the treatment of RA in 
Sweden, the Swedish Biologics Register ARTIS started in collaboration with the Swedish Medical 
Products Agency with the primary aim to evaluate the safety of these drugs. 
The SRQ together with complementary regional initiatives have since provided clinicians and patients 
in Sweden as well as internationally with a large amount of clinically useful information. Major 
strategic advantages of these registers are that they are fully integrated in health care, and used to 
continuously improve care, i.e. they are designed to be useful in daily clinical practice. This design also 
enables patients to have access to their particular information in the register and to provide their own 
patient-derived information, for example from own computers at home or from touch pads in the 
waiting rooms. These features distinguish the Swedish registers from many other registers 
internationally, which are often designed to answer one specific research question, rather than being 
a multipurpose and continuously growing source of information.6 Among other variables, SRQ includes 
date and type of diagnosis, the ACR criteria54 at the time of diagnosis, and data on disease activity, 
disability and treatment. Today SRQ includes data from more than 60 clinics, and covers a high 
proportion (87-95%) of the patients with RA treated with biologics.78,79 The efforts made at the clinics 
in Sweden for entering data into SRQ have resulted in an increasing coverage also of other patient 
groups than in biologic drug users. Depending on the register-based definition, the proportion of 
patients with early RA was 78% in 2012, while an estimated 75% of all individuals with active and 
prevalent RA in Sweden 2012 were included in the SRQ.80 
3.3.2 The randomized Swefot trial 
The aim of the Swefot (SWEdish FarmacOTherapy) trial was to compare the intensive treatment 
alternatives of adding conventional DMARDs or a TNFi (infliximab) in the common clinical situation of 
patients with early RA that have failed their initial treatment with methotrexate monotherapy (Figure 
4).65 The Swefot study was investigator initiated and was funded by the Swedish Rheumatism 
Association and Schering-Plough/Merck Sharp and Dohme. 
Adult patients (aged ≥18 years) with a diagnosis of early RA (symptom duration <1 year) were recruited 
from 15 rheumatology units in Sweden from 2002 through 2005. Key inclusion criteria were fulfilment 
of the 1987 revised ACR criteria,54 a disease-activity score based on DAS28 >3.2,57 no previous DMARD 
treatment, and no or stably dosed oral glucocorticoid therapy for at least 4 weeks, using at most 10 
mg daily prednisolone (or equivalent). Due to the different route of administration of the two 
treatment alternatives, where infliximab is given as an infusion and conventional combination therapy 
is given orally, the use of blinded assessors in the trial was considered but deemed unfeasible owing 
to the limited personnel at smaller participating units. For this reason, the Swefot study was an open-
label trial, where both doctors and patients were aware of the treatment allocation (addition of two 
oral drugs versus one infusion). 
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3.3.2.1 Procedure 
An overview of the trial procedure is presented in Figure 4. At inclusion patients started methotrexate 
monotherapy to be taken every week at an initial dose of 10 mg. The dose was increased every 2 
weeks by 5 mg to 20 mg weekly. After a run-in period of 3-4 months on methotrexate, the DAS28 was 
assessed. Patients with low disease activity (DAS28 <3.2) left the trial, while those with moderate to 
high disease activity (DAS28 ≥3.2) were randomized to receive additional treatment with infliximab (3 
mg/kg body weight, rounded up to the nearest 100 mg increment, given intravenously at weeks 0, 2, 
and 6 and every 8 weeks thereafter) or conventional combination therapy with sulfasalazine and 
hydroxychloroquine (400 mg/day given orally). Patients were scheduled for a visit at the rheumatology 
clinic every 3 months the first year, and thereafter at 18 and 24 months after inclusion to the trial. 
Included subjects could discontinue the assigned treatment at any time for lack of effectiveness, 
adverse effects, or by their own choice. 
3.3.2.2 Treatment adjustments 
In case of adverse events and within the protocol, sulfasalazine and hydroxychloroquine could be 
dose-reduced or withdrawn (while continuing the other), or alternatively, replaced by ciclosporin A 
(2.5 mg/kg/day; increase up to 5 mg/kg/day allowed). Infliximab could be discontinued and replaced 
by etanercept (50 mg subcutaneously/week). 
3.3.2.3 Study outcome 
The primary outcome of the Swefot trial was achievement of a good response in disease activity 
according to the EULAR criteria81 after 1 year of follow-up, which has been reported previously.65 In 
the study protocol, secondary analysis of health economic outcomes were prespecified. In paper III, 
we compared the compensated days of sick leave and disability pension between the treatment arms 
over 21 months, while in paper IV the difference between the arms in both costs and health-related 
quality of life were analyzed by calculating the ICER. 
 
Figure 4 Procedure of the Swefot trial 
RA: Rheumatoid arthritis; DAS28: disease activity score based on 28 joint count;  
EULAR: European League Against Rheumatism 
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3.3.3 National health registers 
The national health registers are kept by the National Board of Health and Welfare, and the national 
health register sources used in this thesis are described here. 
3.3.3.1 The National Patient Register 
The National Patient Register contains inpatient discharges and non-primary outpatient care. The 
inpatient register, also known as the Hospital Discharge Register, started in 1964 and became 
nationwide in 1987 when introducing the ninth revision of the International Classification of Disease 
(ICD) coding system in Sweden. The ICD10 coding system has been used since 1997 (with the exception 
of the county of Skåne where ICD9 was used throughout 1997). Data on every discharge are collected, 
including main and contributory diagnoses from inpatient care. The coverage in terms of registered 
discharges are virtually complete, with close to 100% of all inpatient care reported to the register.82 
The outpatient component started in 2001 and diagnoses are coded according to the ICD10 coding 
system. The coverage is nationwide, but varies with year and specialty. The proportion of outpatient 
visits reported are constantly increasing, and in 2013 87% of all non-primary outpatient care visits in 
somatic care were reported in the register. Most of the non-reported visits were at private 
practitioners.83 
In both the inpatient and the outpatient component, visits are categorized by diagnoses according to 
classification of diagnostic related groups (DRG). Medically similar hospitalizations or non-primary 
outpatient care visits, also with similar resource use, are grouped together based on the main 
diagnosis for the hospital discharge or outpatient visit. This system was initially developed at Yale 
University in the US in the 1960s for quality control in health care, but in Sweden a version adapted 
for Nordic conditions is currently in use (NordDRG). The NordDRG version includes around 580 groups 
in inpatient care and 400 groups in the non-primary outpatient care, and is used for describing the 
case-mix at the hospital, planning, monitoring performance, and for reimbursement of the health care 
delivered. When using DRG for reimbursement purposes, the price per DRG is a fixed price for a 
specific year, and is a weighted average for all the health care delivered in that group and year.83 
The accuracy of the RA diagnosis in the National Patient Register has been validated in a total of 200 
subjects, including 100 prevalent and 100 incident register-identified patients with RA,84 as defined in 
paper I and paper II. In this validation study, 90 patients (90%) in both the prevalent and incident group 
fulfilled either the 1987 ACR or the 2010 ACR/EULAR classification criteria.54,55 Of these 90 patients in 
the incident group, 90% had a register identification date <2 years from date of symptom onset, 
indicating a high validity also in incident patients.84 
3.3.3.2 The Prescribed Drug Register 
The Prescribed Drug Register started in July 2005 and includes data on all dispensed prescription drugs 
in ambulatory care in Sweden, while in-hospital drug use is not recorded on a patient level. Among 
other variables, the register includes the Anatomic Therapeutic Chemical (ATC) code and name of the 
prescribed drug, as well as dosage, route of administration, and price. 
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3.3.3.3 The Cause of Death Register 
The Cause of Death Register started to collect data on deaths and causes of deaths in Sweden in 1961. 
Unlike the National Patient Register where the Swedish version of the ICD coding system is used, the 
causes of death are coded according to the international ICD coding system (www.who.int). 
3.3.4 Demographic registers 
Statistics Sweden (www.scb.se) keeps registers of demographic data. The following register sources 
were used in this thesis. 
3.3.4.1 The Register of the Total Population 
The Register of the Total Population is kept at Statistics Sweden since 1968 and is a subset of the 
population register held at the Swedish Tax Agency (Skatteverket) for tax administration. This register 
includes for example information on birth, sex, residence, civil status, death, country of birth, and 
migration. We used the Register of the Total Population for sampling general population comparators 
to the patients with RA. 
3.3.4.2 Longitudinal Integration Database for Health Insurance and Labor Market Studies (LISA) 
This database includes aggregated data by calendar year since 1990 from both Statistics Sweden, the 
Social Insurance Agency, and the Swedish Agency for Innovative Systems. The focus of the register is 
on the individual but also variables connected to family, companies, and places of employment are 
included. The individual section includes for example data on gainful employment, income, 
compensation from social insurances, and years of education (≤9, 10-12, and ≥12 years). 
From the LISA database and for the included studies, we used only the level of education. The annually 
aggregated data on compensation for sickness or disability could not be used in the analyses including 
sick leave and disability pension (paper II-IV), since these analyses are in relation to a specific date (RA 
onset in paper II, and date of randomization in the Swefot trial in paper III and paper IV). Instead, we 
used data on a daily level directly from registers kept at the Social Insurance Agency. 
3.3.5 Registers at the Social Insurance Agency 
In the registers at the Social Insurance Agency, among other social insurance compensations sick leave 
and disability pension episodes as well as economic compensation are recorded. The sick leave 
(sjukpenning in Swedish) compensation of the first time period is covered by the employer, except the 
1st unpaid day, and during the study period this has been day 2-14. Hence, from day 15 the sick leave 
is registered by the Social Insurance Agency (as 15 days and not as 1 day). Both sick leave and disability 
pension (in Swedish sjukersättning in individuals 30-64y, and aktivitetsersättning in individuals 19-29y) 
can be part-time or full-time (25%, 50%, 75%, or 100%). 
The Social Insurance Agency has established a database for this register where the researcher may 
request data on different perspectives (on an individual level or by benefit), and types of 
compensations.85 Depending on data source used, and in comparison to the annually summarized data 
of sick leave and disability pension in LISA, the analysis may not be straight forward. In our case, where 
we analyzed the total days of work loss adding sick leave and disability pension together (paper II-IV), 
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it could result in that the total compensation in individuals that have had overlapping periods of sick 
leave and disability pension accumulate more than 100% work loss. The reason for this is that sick 
leave is registered as the percentage of the time left after reducing the time on disability pension. For 
example, an individual with 50% disability pension and 100% sick leave during the same period, would 
have a net of half time disability pension and half time sick leave. 
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3.4 STUDY POPULATION AND OUTCOMES 
In this section the study population and the outcomes of each study are described. 
3.4.1 Paper I – Incidence of RA 
In paper I the nationwide register-assessed incidence of RA in Sweden was estimated. We also 
analyzed how the incidence varied across age, sex, geography and demography. In order to describe 
the sensitivity of the register-based definition of incident RA, from a register-based research 
perspective, the robustness of different RA case definitions was tested. 
The overall mean annual incidence during 2006-2008 was estimated, which means that the numerator 
was the number of new cases with RA, also referred to as incident RA, in 2006, 2007, and 2008. The 
denominator was the number of adult residents in Sweden in 2006, 2007, and 2008, respectively 
(population at risk). The cut-off age of 18 years was used as patients in the Swedish health care system 
are not treated in adult care until they turn 18. 
The coverage of patients with new onset RA in the SRQ is high, but not complete (estimated coverage 
78% in 2012).80 To estimate the incidence we therefore also identified patients with RA in the National 
Patient Register. We used both the inpatient and the outpatient component of the register as well as 
both main and contributory diagnoses, and identified patients by using ICD8-10 codes (Table 3). 
Table 3 ICD codes used for identifying patients listing diagnosis for rheumatoid arthritis 
ICD version ICD codes 
ICD10 M05, M06.0, M06.2, M06.3, M06.8, M06.9, M12.3 
ICD9 714A/B/C/W, 719D 
ICD8 712.10/20/38/39 
The base case register-based definition of incident RA required fulfillment of 3 criteria: 
1. Primary identification: Patients ≥18 years with a first ever inpatient or non-primary outpatient 
care visit listing a main or contributory diagnosis for RA, or registered in the SRQ with an 
incident RA diagnosis in 2006-2008. 
2. Follow-up visit: A second discharge or non-primary outpatient care visit for RA within 1 year 
after the first visit. 
3. Exclusion of potential prevalent cases: Patients with any registered DMARD treatment >6 
months before the first visit with RA were excluded. 
A more liberal as well as a more strict definition were tested. In the liberal definition, we used the 
same definition as in the base case, but without criterion 3. In the strict definition, the criterion of at 
least one of the visits should be at a rheumatology or internal medicine department was added. 
We estimated crude incidence rates as well as standardized to age, sex, and/or level of education of 
the Swedish population in 2008. 
In this study we also assessed the anti-rheumatic treatment penetration of biologic and non-biologic 
DMARDs, and glucocorticoids by collecting data on prescriptions of non-infusion drugs from the 
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Prescribed Drug Register according to ATC codes (Table 4), while infusion biologic drug use was 
collected from the SRQ (abatacept, infliximab, rituximab, and tocilizumab). 
Table 4 ATC codes used for identifying prescriptions of DMARDS and glucocorticoids 
Drug group Drug ATC codes 
Non-biologic DMARDs 
Auranofin M01CB03 
Azathioprine L04AX01 
Ciclosporin L04AD01 
Hydroxychloroquine P01BA02 
Chloroquine P01BA01 
Methotrexate 
L01BA01 
L04AX03 
Sodium aurothiomalate M01CB01 
Sulfasalazine A07EC01 
Biologic DMARDs 
Abatacept L04AA24 
Adalimumab L04AB04 
Anakinra L04AC03 
Certolizumab pegol L04AB05 
Etanercept L04AB01 
Golimumab L04AB06 
Infliximab L04AB02 
Rituximab L01XC02 
Tocilizumab L04AC07 
Glucocorticoids Prednisolone H02AB06 
 
3.4.2 Paper II – Costs for hospital care, drugs and lost work days in RA 
In this study the annual costs for health care and lost work days in patients with prevalent and incident 
RA were assessed. Incident cases were defined as the base case definition in paper I, but using 2009 
as the primary identification year instead of 2006-2008. Prevalent cases were defined as alive and 
living in Sweden on 1 January 2010, with ≥2 visits listing RA from the National Patient Register and/or 
included with a diagnosis of RA in the SRQ. All costs for the patients with RA were compared to their 
comparators matched 5:1 on age, sex, education level, residence, and year, in order to obtain a 
benchmark for the cost attributable to the RA disease. 
Costs for hospital care, drugs, and lost work days were assessed during 2010 in prevalent patients, 
while for incident patients these cost components were collected during 1 year of follow-up from the 
register identification date (1st ever visit listing RA in 2009). In the analysis costs were estimated in SEK, 
but converted to 2010 euros (€1 = 9.54 SEK in 2010) in the presented results. 
3.4.2.1 Health care costs 
To estimate the cost for hospital admissions and visits in non-primary outpatient care the price per 
DRG was used. This is a weighted average of costs per diagnostic related group, and is supposed to 
cover the expenses for the hospital of the health care delivered. 
Costs for drugs, except for infusion drugs, were collected directly from the Prescribed Drug Register, 
while data on in-hospital drug use given by infusion (abatacept, infliximab, rituximab, and tocilizumab) 
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were collected from the SRQ and turned into costs by using the 2010 drug costs in Sweden 
(www.tlv.se). 
3.4.2.2 Productivity losses 
In the main analysis the value of work days lost was estimated by using the human capital approach, 
including all days on sick leave and disability pension during follow-up. To estimate the productivity 
losses, we multiplied the accumulated days of work loss with the average Swedish salary, including 
social fees (31%), in 2010 (www.scb.se). In order to simplify comparisons to some previous cost studies 
of RA, we also valued the work loss by using the friction cost method in sensitivity analysis, with a 
friction time of 6 months for individuals to be replaced. 
3.4.3 Paper III – Infliximab versus conventional combination treatment and work loss 
in early RA 
Patients not responding to initial methotrexate monotherapy were randomly assigned to the addition 
of either infliximab (also referred to as biological treatment group) or sulfasalazine and 
hydroxychloroquine (conventional treatment group, also referred to as triple therapy; Figure 4). Days 
of sick leave and disability pension, with a maximum of 30 compensated days/month, were analyzed 
in all patients <63y (retirement age was 65y during the study period) who had undergone 
randomization. In the main analysis, all randomized patients were included using the ITT approach, 
and the sum of monthly sick leave and disability pension days was compared between the treatment 
arms at 12 and 21 months after randomization. A few patients never received their allocated 
treatment, and were removed in a modified intention-to-treat analysis. In addition, we also conducted 
a per protocol analysis in all patients that completed the treatment 1 and/or 2 years according to the 
protocol. Finally, to describe the work loss development in comparison to the general population, we 
also computed the sick leave and disability pension days in matched general population comparators 
included in the register-enriched database. 
3.4.4 Paper IV – Cost-effectiveness of infliximab versus conventional combination 
treatment in early RA 
All randomized patients, both working age as well as retired, in the Swefot study were included in this 
cost-effectiveness analysis. We analyzed both the accumulated societal costs and health-related 
quality of life during 21 months of follow-up (from randomization to end of trial) by computing the 
ICER. 
3.4.4.1 Estimation of costs 
We performed the cost-effectiveness analysis both from the health care and the societal perspective. 
Included cost components were anti-rheumatic drugs, inpatient care, non-primary outpatient care, 
sick leave, and disability pension. As in paper II, we assessed costs for hospital admissions and visits in 
non-primary outpatient care using the weighted average price per DRG. 
Anti-rheumatic drug use was collected from the SRQ, where anti-rheumatic treatment information 
were recorded during the Swefot trial. Data on drug prescriptions from the Prescribed Drug Register, 
which started in July 2005, was not available for all patients during their follow-up. Drug doses and 
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frequencies for biologics, conventional DMARDs, glucocorticoids, and non-steroidal anti-inflammatory 
drugs was turned into costs by using the 2011 drug prices in Sweden (www.tlv.se). 
Productivity losses were estimated similarly as in paper II. Complete and objectively assessed day level 
data on sick leave and disability pension were available from the registers at the Social Insurance 
Agency. We used the human capital approach for estimating the productivity losses in the main 
analysis, and the friction cost method, with a friction period of 6 months for individuals to be replaced, 
in sensitivity analysis. 
All costs were converted to 2011 euros (€1 = 9.03 SEK in 2011). 
3.4.4.2 Estimation of quality adjusted life years (QALYs) 
EQ-5D utility was collected quarterly in the Swefot trial. We calculated the area under the curve for 
the utility scores plotted against time using the trapezoid method, where the area under the curve 
represents the accumulated QALYs during follow-up. The UK EQ-5D preference set was used in the 
main analysis. We also conducted a sensitivity analysis with the EQ-5D US tariff. 
3.4.4.3 Discounting 
In cost-effectiveness analysis the general recommendation is to apply an annual discount rate on both 
costs and effects. In this study, given the short follow-up time with only 9 months beyond the first year 
considered for discounting, the results are presented undiscounted. 
3.4.4.4 ICER 
The ICER was calculated by taking the difference in cost divided by the difference in QALYs between 
the infliximab arm and the conventional treatment arm. 
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3.5 STATISTICAL ANALYSIS 
All statistical methods for analyzing the data included in this thesis are presented here. 
3.5.1 Poisson distribution 
The Poisson distribution was used to describe the uncertainty around the incidence rate in paper I, by 
assuming that the number of incident cases followed this distribution. 
The Poisson distribution is a discrete probability distribution that is used to describe the variability 
around a known average rate of occurrence. If an average rate is known, and the events occur 
independently of the time since the last event, the Poisson distribution describes the probability that 
a given number of events will occur.26 
3.5.2 Kaplan-Meier estimator 
In paper III the time to discontinuation by the randomly allocated treatments (infliximab versus 
conventional treatment group) are presented in a Kaplan-Meier survival curve. 
The Kaplan-Meier estimator measures, over time, the fraction of subjects that have not had the event 
of interest, i.e. the probability of each event at the time it occurs.86 This method is widely used in 
survival analysis, due to its efficient use of the available information in censored data. 
3.5.3 Cox regression 
A Cox regression model was fitted in paper III, and presented together with the Kaplan-Meier survival 
curve, to assess the between-group differences in time to discontinuation by the randomly allocated 
drug (infliximab versus conventional treatment group). 
Cox regression, or Cox proportional hazard regression, is widely used in survival analysis where the 
time, which may be associated to any characteristics included in the model, to any event is analyzed.25 
The hazard ratio is computed between the exposed and unexposed group for a certain characteristic, 
and is defined as the ratio of new cases per population at risk per unit time between the groups that 
are compared. As noted in the name, the hazards are assumed to be proportional over time. Therefore 
no assumptions need to be made about the shape of the underlying risk distribution since the baseline 
hazard is canceled out in the regression formula. For this reason Cox regression is usually considered 
to be a semi-parametric model. 
3.5.4 Analysis of covariance 
In paper III we used analysis of covariance (ANCOVA) to estimate the differences at 12 and 21 months 
after randomization in compensated days of sick leave and disability pension between the treatment 
arms (infliximab versus conventional treatment group). The analysis was adjusted for days of work loss 
during the 30 days before randomization. 
ANCOVA is a general linear model that mixes analysis of variance (ANOVA) and regression. When 
comparing two groups using a continuous outcome, two parallel straight lines are obtained relating 
outcome to any covariates in the model. Advantages of using ANCOVA with baseline and follow-up 
measurements are that it generally has greater statistical power to detect a treatment effect 
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compared to other methods, such as change score analysis, but foremost, it is a powerful method to 
measure change from baseline to follow-up by adjusting for potential baseline imbalances between 
groups.87 
In our example, we estimate the difference between the treatment groups and adjust this difference 
in work loss to what it would be if everyone had the same number of days of work loss before 
randomization. 
The ANCOVA in paper III can be expressed as a single regression equation: 
𝑊𝑜𝑟𝑘𝐷𝑎𝑦𝑠𝐿𝑜𝑠𝑡12/21𝑚𝑜𝑛𝑡ℎ𝑠 = 𝛽0 + 𝛽1𝐺𝑟𝑜𝑢𝑝 + 𝛽2𝑊𝑜𝑟𝑘𝐷𝑎𝑦𝑠𝐿𝑜𝑠𝑡𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 +  𝜀 
where β0 is a constant (intercept), β1 is the effect of interest (i.e. the difference between the treatment 
arms), and β2 the effect of baseline adjustment. 
Since the estimated difference between two groups is the vertical distance between the regression 
lines, one assumption using ANCOVA is that the slopes of the regression lines for the groups should be 
equal, i.e. they should be parallel. Other assumptions include linear relation between the dependent 
variable and covariates, and normal distribution of the error terms (but not necessarily for the 
dependent variable or covariates). 
3.5.5 A note on statistical power in the Swefot trial 
Aiming for enrollment of 600 patients, the Swefot trial was initially designed to detect a difference of 
15% in the treatment effect, based on disease activity using the EULAR criteria,81 between the 
infliximab and the conventional treatment arm with a statistical power of 90% (α=0.05). With slower 
recruitment of patients to the trial than anticipated, in the end, a total of 487 patients were enrolled 
to the study, resulting in a reduced estimated statistical power to 75%. 
In paper III, 105 and 99 patients of working age were included in the infliximab and the conventional 
treatment group, respectively, for comparison of monthly days of sick leave and disability pension 
between the treatment arms. The number of patients needed at a given power to detect a difference 
of 2-6 work loss days per month is presented in Figure 5. For example, with 100 patients in each group, 
a mean difference of 5 days/month between the treatment arms can be detected at a power of 85%. 
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Figure 5 Number of patients per group needed to detect a mean difference of 2-6 days per month of sick leave 
and disability pension between the infliximab and the conventional treatment arm  
to a power ranging from 50% to 90% 
3.5.6 Incremental cost-effectiveness ratio (ICER) 
In paper IV we computed the ICER between the two treatment strategies of the Swefot trial as the 
difference in the accumulated costs divided by the difference in accumulated effects between the 
infliximab and the conventional treatment arm. 
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝐼𝑛𝑓𝑙𝑖𝑥𝑖𝑚𝑎𝑏 − 𝐶𝑜𝑠𝑡𝐶𝑜𝑛𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝐸𝑓𝑓𝑒𝑐𝑡𝐼𝑛𝑓𝑙𝑖𝑥𝑖𝑚𝑎𝑏 − 𝐸𝑓𝑓𝑒𝑐𝑡𝐶𝑜𝑛𝑣𝑒𝑛𝑡𝑖𝑜𝑛𝑎𝑙 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
 
Since the ICER is a ratio it is not straight forward to compute the uncertainty of the ICER point estimate. 
However, one method for estimating the uncertainty around the ICER point estimate is to use non-
parametric bootstrapping,88 and present the result in a scatterplot in the cost-effectiveness plane, or 
as a probability of the ICER point estimate to be below a certain willingness-to-pay per QALY ratio in a 
cost-effectiveness acceptability curve. 
3.5.7 Seemingly unrelated regression 
We used a seemingly unrelated regression equation89 for computing the ICER for the infliximab 
compared to the conventional treatment group in paper IV. The analysis was adjusted for potential 
baseline imbalances in age, sex, EQ-5D, DAS28 and health assessment questionnaire (HAQ) scores at 
randomization, as well as accumulated costs during 60 days before randomization. It was also 
repeated unadjusted for other covariates. 
Compared to ordinary least square regression, the seemingly unrelated regression method has the 
advantage of capturing correlation between costs and effects and might result in higher efficiency.89 
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3.5.8 Bootstrapping 
The uncertainty around the mean estimates of costs, effects, and the ICER in paper IV was assessed 
using non-parametric bootstrapping with 1000 iterations. In paper II we used bias-corrected and 
accelerated bootstrapping90 to estimate the between-group difference in days of work loss with 95% 
confidence intervals. 
Bootstrapping is a technique where sampling is performed on the existing data. Since no assumptions 
on the underlying distribution is made, bootstrapping is useful in situations where the variable of 
interest is skewed. A number of iterations of sampling with replacement (usually ≥1000) are applied, 
and for each of the iterations statistics are computed.91 
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4 RESULTS 
In this section the results from each study is presented. 
4.1 PAPER I 
In 2006 to 2008, 8826 individuals were identified as incident RA according to the base case definition, 
which corresponded to an overall incidence of 40.6 per 100,000 (95% CI 39.7 to 41.4). The overall 
incidence in women (55.7 per 100,000; 95% CI 54.3 to 57.1) was more than twice the incidence 
observed in men (25.0 per 100,000; 95% CI 24.0 to 25.9). 
In age and sex specific analysis we observed an increasing incidence with age until the 70-79 years age 
group, with 102 per 100,000 for women and 67 per 100,000 for men, and thereafter the incidence 
decreased in the oldest (Figure 6). 
When using the liberal definition of incident RA, the overall incidence estimate increased to 46.4 per 
100,000 (+14%), while when using the strict definition the incidence estimate decreased to 36.8 per 
100,000 (-9%; Figure 6). We also noted a high biologic and non-biologic DMARD penetration from 6 
months before until 2 years after first RA diagnosis across all definitions (>90%) as well as across age 
groups (>90% in all age groups except patients ≥80 years old). 
Although no geographic gradient was found, we found a clear gradient across population density and 
level of education, with lower standardized estimates in population dense areas and among individuals 
with higher education level (51 to 44 to 33 per 100,000 in individuals ≥9 years, 10-12 years, and >12 
years, respectively). 
 
 
Figure 6 Mean annual register-based incidence of rheumatoid arthritis (RA) per 100,000 by sex and age for the 
liberal, base case and strict definition of RA. The overall incidence by case definition is indicated in parentheses. 
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4.2 PAPER II 
Of 49,829 patients identified as prevalent RA, the mean annual cost per patient in the 18-64 years 
group was €23,147 (versus €8364 in matched general population comparators), where 75% was 
accounted for by productivity losses, and only 25% by health care costs (Figure 7). In the ≥65 years 
group the mean health care cost was €6438 (versus €2773 in comparators). 
Among the prevalent patients with RA using biologics the mean annual total cost in 18-64 years was 
€32,626, and in the ≥65 years group €15,235, which was 4 and 6-7 times the cost in their matched 
general population comparators, respectively. In non-biologic users the mean total cost was €19,628 
in the 18-64 years group and €5275 in the ≥65 years group. 
Among the patients with incident RA (n=2695), the mean monthly cost increased from a level close to 
the matched general population comparators 12 months before the register identification, peaked the 
month following the identification date, and decreased to twice the cost of the comparators 1 year 
thereafter (Figure 8). One year after the register identification, the monthly societal cost in the 18-64 
years group was €1252 versus €628 in the comparators (mean difference €624; 95% CI 517 to 740). 
Among the older patients the monthly health care cost was €487 versus €230 in the comparators 
(mean difference €258; 95% CI 181 to 350). 
The cost distributions were heavily right skewed in both the incident and the prevalent patients with 
RA, with approximately 13% of the patients accounted for 50% of the annual total cost. 
 
 
Figure 7 Mean (bars) and median (black dots) annual costs in patients with prevalent rheumatoid arthritis (RA), 
prevalent RA treated with biologics, and matched general population comparators 
RA treated with biologics: patients with RA, with any dispensed non-infusion biologics in 2009, or with an 
ongoing treatment of infusion biologics on 1 January 2010; Comparators: general population comparators 
matched 5:1 by age, sex, education level, place of residence, and year. 
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Figure 8 Mean (bars) and median (black dots) monthly costs in patients with incident rheumatoid arthritis (RA) 
18-64 years (upper panel) and ≥65 years (lower panel), and mean monthly cost  
in comparators (white diamonds), in relation to register identification date 
Comparators: general population comparators matched 5:1 by age, sex, education level, place of residence, 
and year.  
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4.3 PAPER III 
Out of 493 patients that were screened for inclusion to the Swefot trial from October 2002 through 
December 2005, 487 were enrolled in the study. Of 258 randomized patients, with DAS28 >3.2 after 
3-4 months of methotrexate monotherapy, 204 were <63 years at randomization, whereof 105 were 
randomly allocated to infliximab and 99 to conventional combination treatment. Seven patients in the 
infliximab and 4 in the conventional treatment group never received the study drug. In the infliximab 
arm 69% (n=72) followed the study per protocol for 21 months, while 53% (n=52) in the conventional 
treatment arm completed the study according to protocol. The hazard ratio for the difference in time 
to discontinuation in the infliximab compared to the conventional treatment group at 21 months after 
randomization was 0.51 (95% CI 0.31 to 0.82). 
Mean sick leave and disability pension days at randomization were 17 days/month in both groups 
(mean difference 0.6; 95% CI -3.0 to 3.9). Using the ITT approach, the mean changes in sick leave and 
disability pension at 21 months after randomization were -4.9 days/month in the infliximab and -6.2 
days/month in the conventional treatment group (adjusted mean difference 1.6; 95% CI -1.2 to 4.4). 
Excluding patients that never received the study drug in a modified ITT analysis, the adjusted mean 
difference was 1.5 days/month (95% CI -1.5 to 4.4), and in per-protocol analysis the adjusted mean 
difference was 0.3 days/month (95% CI -2.8 to 3.8). 
Similar to the results at 21 months after randomization, no significant differences were observed in 
ITT, modified ITT, or per-protocol analyses at 12 months after randomization. 
Work loss in relation to general population comparators 
At 1 year before randomization, the overall mean monthly days of sick leave and disability pension 
started to increase from the same level as in the general population (5 days/month), and increased to 
20 and 18 days/month in the (future) infliximab and the conventional treatment groups, respectively, 
at the start of the run-in period (Figure 9). Compared to the general population, the randomized 
patients reduced their monthly days of sick leave and disability pension from a level 3 times greater at 
randomization to twice the days at 21 months after randomization, with most of the observed 
reduction already present after 6 months. 
Work loss in non-randomized patients 
Patients of working age who after the run-in period did not undergo randomization, most of whom 
responded to the methotrexate monotherapy (defined as a DAS28 ≤3.2; n=135), started from a lower 
level at the time of methotrexate monotherapy initiation as compared to the randomized patients. 
The non-randomized group decreased their monthly work loss days from 12 to 8 days/month during 
the run-in period, and further decreased their work loss days to the level of the general population 7 
months thereafter (6 days/month; Figure 9). 
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Figure 9 Mean monthly days on sick leave and disability pension in relation to date of randomization 
(maximum 30 days) 
Run-in period: Methotrexate monotherapy; Controls: General population comparators matched 5:1 by age, 
sex, education level, place of residence, and year; error bars: SEs; Infliximab: Infliximab plus methotrexate; 
Conventional treatment: Sulfasalazine and hydroxychloroquine plus methotrexate; Non-randomized: Non-
randomized patients of whom a majority had a favorable DAS28 response after the run-in period. 
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4.4 PAPER IV 
Out of the 258 randomized patients in the Swefot trial, 128 were randomized to infliximab and 130 to 
conventional combination treatment. A few patients never received the randomly allocated drug (8 
patients in the infliximab group and 5 patients in the conventional treatment group). A higher 
proportion of patients in the infliximab arm completed 2 years of follow-up compared to the 
conventional treatment arm, 70% (n=90) versus 57% (n=74), respectively. 
Costs 
With the high cost of infliximab, the patients in the infliximab arm incurred higher health care costs 
compared to the conventional treatment arm (€19,215 versus €4710; adjusted mean difference 
€14,280; 95% CI 12,269 to 16,101; Figure 10). Furthermore, the patients in the infliximab group had 
more rheumatology clinic visits, resulting in higher costs of health care use than the conventional 
treatment group (€8272 versus €5653; adjusted mean difference €2676; 95% CI 1425 to 4058). 
In the main analysis using the human capital approach, no difference in productivity losses was 
detected between the infliximab and the conventional treatment group (€33,804 versus €29,220; 
adjusted mean difference €3961; 95% CI -3986 to 11,850). A similar result was obtained in sensitivity 
analysis when instead the friction cost method was applied for valuation of productivity losses. 
The higher health care costs in the infliximab arm resulted in higher total costs from both the societal 
(€61,291 versus €39,584; adjusted mean difference €20,916; 95% CI 12,800 to 28,660) and the health 
care perspective (€27,487 versus €10,364; adjusted mean difference €16,956; 95% CI 14,647 to 
19,162). 
QALYs 
During the 21 months of follow-up from randomization, the infliximab group accumulated on average 
1.10 QALYs while the conventional treatment group accumulated on average 1.12 QALYs (adjusted 
mean difference favoring the infliximab arm 0.01; 95% CI -0.07 to 0.08).92 
Incremental cost-effectiveness ratio (ICER) 
Including productivity losses the ICER from the societal perspective between the infliximab and the 
conventional treatment group was €2,404,197 per QALY, while only including health care costs the 
ICER from the health care perspective was €1,948,919 per QALY (Figure 11). As Figure 11 indicates, no 
bootstrap sample was cost saving for the infliximab compared to the conventional treatment group, 
and 60% of the bootstrap samples displayed a higher accumulated QALY in the infliximab arm and thus 
presented in quadrant I. 
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Figure 10 Specific and total costs from the health care and societal perspective  
for the infliximab versus the conventional treatment strategy 
Infliximab: Infliximab plus methotrexate;  
Conventional treatment: Sulfasalazine and hydroxychloroquine plus methotrexate. 
 
 
Figure 11 The point estimate and bootstrapped incremental cost-effectiveness ratio  
plotted in the cost-effectiveness plane by societal and health care perspective  
for the infliximab versus the conventional treatment strategy 
WTP: willingness to pay 
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5 DISCUSSION 
5.1 MAIN FINDINGS 
This thesis describes how register-enriched quality of care register data can be used in studying the 
occurrence and burden of disease, including considerations of possible limitations with register-
identification of cases. Furthermore, with a randomized pragmatic clinical trial included in the register 
framework, we have provided information on health economic outcomes to a common clinical 
question in early RA, namely whether to continue treatment by adding a biologic alternative or to 
continue with a conventional combination treatment strategy after insufficient response to 
methotrexate. 
More specifically, by enriching the SRQ with data from Swedish national health registers, demographic 
registers, and the registers at the Social Insurance Agency, the aims of this thesis were to (i) estimate 
the nationwide incidence of RA in Sweden overall and across subgroups of age, sex, demography, and 
geography, (ii) estimate the annual burden in terms of costs of hospital care, drugs, and lost work days 
in incident and prevalent RA, (iii) compare the effect on work loss in a treatment strategy of adding 
infliximab versus adding further conventional DMARDs in patients with methotrexate-refractory early 
RA, and (iv) to estimate the incremental cost-effectiveness of the infliximab versus the conventional 
treatment strategy. 
5.1.1 Incidence of RA 
We estimated the nationwide incidence of RA in Sweden to 41 per 100,000. The incidence in women 
and men was 56 and 25 per 100,000, respectively, and increased considerably with age with a peak in 
the 70-79 years age group in both sexes. Using age- and sex standardized estimates, lower incidences 
were observed in densely populated areas and in individuals with high education level, but no 
geographic trends were detected. Changing the register-based case definition of RA to a more liberal 
and a more strict definition, respectively, altered the incidence estimates by less than 15%. 
5.1.2 Costs for hospital care, drugs, and lost work days in RA 
In 22,000 prevalent working age patients with RA the mean annual societal cost was €23,000, of which 
one quarter was attributed health care costs and three quarters to productivity losses. This cost was 
2-3 times higher than the corresponding costs in general population comparators, resulting in an 
estimated annual cost of €15,000 attributable to RA. The corresponding mean annual incremental cost 
in retirement age prevalent patients with RA (n=28,000) was €4000, with inpatient care as the largest 
cost component. 
In new onset RA, the mean monthly cost increased from a level close to that of the general population 
12 months before the first registered RA diagnosis. A peak in mean monthly costs was observed one 
month after the identification date of RA diagnosis, and then decreased to twice the cost as compared 
to the general population 12 months thereafter. 
The cost distributions were heavily skewed, with less than 15% of the patients contributed with more 
than half of the total annual cost. 
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5.1.3 Infliximab versus conventional combination treatment and work loss in early RA 
In patients with early RA and an insufficient response to methotrexate monotherapy who were 
randomly allocated to receive infliximab or conventional combination therapy in addition to 
methotrexate, the monthly days of sick leave and disability pension were significantly reduced over 21 
months. However, no difference in work loss days could be detected when comparing the strategies 
of adding infliximab or adding further conventional DMARDs after methotrexate failure. At 12 months 
before randomization, the monthly work loss days started to increase from the same level as the 
general population. At randomization, the observed level of 17 days/month in both treatment arms 
was 3 times the days in the general population, and at 21 months after the randomization the work 
loss days were double that in the general population. 
Even though the randomized patients did not have a favorable DAS28 response at 3 months, they 
reduced their work loss days over this run-in-period. However, the observed improvement was much 
greater in the non-randomized patients, most of whom had a favorable DAS28 response (Figure 9). 
5.1.4 Cost-effectiveness of infliximab versus conventional combination treatment in 
early RA 
Over 21 months we observed higher drug and health care costs in patients with methotrexate-
refractory early RA who were randomly allocated to infliximab, as compared to those who were 
randomized to receive conventional combination therapy, while no differences in productivity losses 
or QALYs between the treatment strategies could be detected. The incremental cost-effectiveness 
ratios for the infliximab versus the conventional treatment strategy were €2,400,000/QALY from the 
societal perspective and €1,900,000/QALY from the health care perspective. Given willingness to pay 
levels that are generally considered to be acceptable (US$50,000-100,000 or £20,000-30,000 per 
QALY),93-95 the infliximab strategy, as compared to the conventional alternative, was not found to be 
cost-effective over 21 months in this trial. 
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5.2 PREVIOUS RESEARCH 
5.2.1 Incidence of RA 
Previous estimates of RA incidence in Sweden have been reported from regional studies from southern 
Sweden that found more than a 2-fold variation, with 24 versus 50 cases per 100,000.96,97 The larger 
and most recent study by Englund and colleagues reported a higher overall incidence estimate in 2008 
as compared to our estimate (50 versus 41 per 100,000). With the exception of their regional and our 
national study approach, the discrepancy between their study and ours may be due to our better 
possibilities of excluding prevalent RA patients through both a longer washout period and access to 
prescription drug data. 
An incidence study from the US based on 466 cases between 1995-2007 from Minnesota has been 
reported by Myasoedova and colleagues.98 Although we used a different study design and case 
ascertainment technique, the overall (their 41 versus our 41 per 100,000) and age as well as sex-
specific incidence estimates were remarkably similar to our estimates. 
As for European countries, incidence estimates have been reported from Finland (45 per 100,000),53 
Denmark (31 per 100,000),99 the UK (25 per 100,000),100 and Italy (35 per 100,000).101 In the reports 
from Italy, Denmark, and Minnesota, as in our study, the incidence of RA was found to peak in the 6th-
7th decade of life in both women and men, while the studies from Finland and the UK reported a more 
widespread peak before age 60 years. However, another study using the same cohort from Norfolk in 
the UK,100 but with longer follow-up time (5 years) for estimating the incidence of RA, still found a 
widespread peak in women, but with an incidence of 54 per 100,000 in women and 24 per 100,000 in 
men,102 which is more comparable to our estimates. Furthermore, in that study, applying the 2010 
ACR/EULAR classification criteria at baseline was similar to the estimates using the 1987 ACR 
classification criteria cumulatively over 5 years.56 
5.2.2 Costs for hospital care, drugs, and lost work days in RA 
A recent review compiled data on cost of illness studies in RA with a comprehensive discussion about 
difficulties in comparisons between studies due to different methodological approaches, health care 
settings, and study objectives of the reviewed reports.103  
Despite these difficulties, another review tried to estimate a weighted mean annual cost based on 
data from 26 cost of illness studies in RA.104 They reported a mean annual cost per prevalent RA patient 
of €4170 in health care costs and €8452 in productivity losses. Our total cost estimates accumulated 
over 1 year were substantially higher with €6352 in health care costs and €16,907 in productivity 
losses. More comparable estimates resulted when subtracting the cost of the general population 
comparators (€4228 in excess health care cost and €9816 in productivity losses). However, our 
estimates were still higher. One reason for the discrepancy may be that the weighted mean annual 
cost estimates in the review were partly based on studies before or very early in the biologic era (8 
studies published before 2003). 
As with previous estimates of the incidence of RA, cost estimates have also been reported based on 
questionnaire data from southern Sweden in patients with established RA.72 The mean annual cost per 
patient was estimated to approximately €12,000 (ours €13,665), with productivity losses accounting 
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for 55% of the total cost (73% in our study). Although this study was conducted in a regional sample 
in the early biological era, the estimates are largely in keeping with ours. However, this study also 
included cost components that we did not have access to, i.e. costs associated to primary care visits, 
community services and transportation, patient costs, and informal care, which together accounted 
for 18% of the estimated total cost in the study. 
With respect to productivity losses during the first year in newly diagnosed patients with RA, an overall 
cost estimate in the working age population of the FIN-RACo trial from Finland,105 was reported to be 
€8320 in 2002.106 In their study, RA-related disability pension and sick leave for any reason were 
included in the analysis. Reducing our estimate of productivity losses with the corresponding costs in 
the general population comparators resulted in an estimated work loss cost attributable to RA of 
€6560. With the exception of the sick leave estimates due to any reason in their study, the discrepancy 
may also be explained by more aggressive treatment alternatives in our study as well as stricter 
regulations in the welfare system in Sweden during recent years, with decreasing days of both sick 
leave and disability pension during the recent decade in patients with RA.8,107 
5.2.3 Infliximab versus conventional combination treatment and work loss in early RA 
Data from RCTs including patients with early RA have shown that the most used TNF inhibitors in RA 
(infliximab, etanercept, and adalimumab) in combination with methotrexate are clinically and 
radiologically superior to methotrexate alone.15,108,109 However, the recent double-blind randomized 
controlled TEAR (Treatment of Early Aggressive Rheumatoid Arthritis) trial showed similar results in 
disease activity and small differences in radiographic progression after 2 years, as was found from the 
Swefot trial,66 in treatment strategies of patients randomly allocated to methotrexate plus etanercept 
or triple therapy, regardless of immediate initiation or following insufficient response to methotrexate 
monotherapy.64 From the same trial, similar estimates in disease activity and small differences in 
radiographic progression were observed after 2 years between groups of subjects who were 
randomized to immediate methotrexate monotherapy who thereafter had a sufficient response after 
24 weeks (DAS28 <3.2), to immediate methotrexate with step-up combination therapy at 24 weeks 
due to insufficient response (DAS28 ≥3.2), and to immediate methotrexate in combination with 
sulfasalazine and hydroxychloroquine or to methotrexate plus etanercept.110 
In studies based on self-reported data, early treatment initiation after diagnosis, as compared to 
starting treatment later in the disease course, has been shown to have a stronger effect on work 
loss.111,112 Several studies have reported the impact of biological agents on work participation,113 
where only four identified studies have used an RCT design.13-16 All four studies compared TNFi plus 
methotrexate with methotrexate alone, and found a significant improvement favoring the TNFi 
therapy. However, none of the studies compared TNFi plus methotrexate to combination DMARD 
therapy, analyzed the effect in methotrexate refractory early RA, and all used self-reported work loss 
data. These study characteristics compounded with the addition to different approaches to assess 
work loss and different follow-up periods complicate comparisons between these studies and ours. 
The FIN-RACo trial reported that a strategy of starting combination DMARD therapy is superior to 
single DMARD therapy in early RA.105 Rather than using single DMARD therapy as comparison, it 
appears therefore more reasonable to compare a biologic combination alternative to a combination 
DMARD therapy. 
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5.2.4 Cost-effectiveness of infliximab versus conventional combination treatment in 
early RA 
To the best of our knowledge, no previous study from a randomized trial has presented cost-
effectiveness results based on directly observed costs and quality of life in methotrexate-refractory 
early RA. 
The BeSt trial compared four different treatment strategies in patients with early RA,63 and found that 
a strategy of initial infliximab plus methotrexate therapy resulted in more QALYs and less productivity 
losses, as compared to initial combination therapy with methotrexate, sulfasalazine, and 
prednisone.114 However, the analysis has been criticized for not adjusting for potential imbalances in 
baseline productivity, with the argument that substantial differences in incremental costs were 
observed when assessing productivity losses using the human capital or the friction cost method.115 
Comparisons with our results to the results from the BeSt study may be difficult. The BeSt study did 
not include a strategy starting with triple therapy and patients had not previously failed methotrexate, 
while work loss and utility were improved already during the run-in period of methotrexate 
monotherapy in the Swefot trial. 
As discussed, the randomized double-blind TEAR trial showed similar clinical outcomes and small 
although statistically significant radiographic differences between four treatment strategies after 2 
years in early RA patients. In this trial, patients were randomly allocated to immediate etanercept plus 
methotrexate, immediate triple therapy, or to two different step-up strategies with the same 
treatment alternatives but with immediate methotrexate monotherapy as first-line treatment. 
Preliminary results presented in abstract form in a life-time horizon cost-effectiveness modelling study 
based on the TEAR trial indicate that the strategy of immediate etanercept plus methotrexate, as 
compared to the immediate triple therapy strategy, was not found to be cost-effective in relation to 
what most health care settings consider to be acceptable (ICER = $837 100).116 
Similar clinical and radiographic outcomes have also been reported after 5 years of follow-up in the 
NEO-RACo trial,117 where patients with early RA were randomly allocated to receive immediate 
therapy with infliximab or placebo, in addition to combination therapy with methotrexate, 
sulfasalazine, hydroxychloroquine, and prednisolone.67 Finally, in patients with established RA 
included in the double-blind randomized noninferiority RACAT (Comparison of Active Therapies) trial, 
triple therapy was also found to be noninferior to methotrexate plus etanercept after 48 weeks of 
follow-up regarding disease activity and radiographic progression.68 Although no health economic 
analysis has been presented from either the NEO-RACo or the RACAT study, the higher drug cost in 
the TNFi arm would likely favor the conventional treatment strategy. 
5.3 IMPLICATIONS 
Using a register-enriched quality of care register methodology enables a strong observational study 
design with long-term follow-up of real-world patients for many different outcomes and to an 
affordable cost. In contrast, while the RCT is one of the most powerful tools available in medical 
research, randomized trials are often very expensive to conduct leading to a limited number of 
patients enrolled, or that the intended trial may not be conducted at all, with potential power issues 
and concerns relating to representativeness of the results. By combining the randomization procedure 
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in a pragmatic clinical trial setting with the observational register-enriched platform, the study design 
becomes far more powerful enabling safety, effectiveness, and cost-effectiveness assessments of 
treatment alternatives in a large sample and to a low additional cost, while at the same time 
accounting for unmeasured confounders and selection bias. With the improvement and enormous 
opportunities to conduct effective medical research in relation to cost when combining strengths from 
randomized trial and prospectively recorded register data,10,118,119 and given that over 80 Swedish 
registers are of sufficient quality to be certified as quality of care registers, efforts should be prioritized 
to enable randomized register trials to a higher extent in medical research in Sweden. 
With respect to methotrexate-refractory patients with early RA in the Swefot trial, over 21 months, 
work loss and quality of life improved similarly in a treatment strategy of adding infliximab as 
compared to adding further conventional DMARDs to methotrexate, while higher costs were observed 
in the infliximab arm. Based on these results, an attempt with conventional combination therapy 
appears reasonable before starting infliximab treatment, both from a clinical and economic 
perspective. However, less radiographic progression was observed in those patients starting infliximab 
therapy after methotrexate failure, why larger studies and longer follow-up may be warranted to 
confirm the study conclusion. 
In addition to the non-responders of methotrexate monotherapy who were randomized to a 
combination therapy in the Swefot trial, we also analyzed work loss outcomes in the non-randomized 
group, and observed a substantial decline in monthly work loss days after methotrexate monotherapy 
initiation. In less than a year after the month of run-in, the average number of monthly work loss days 
was at the same level as the general population, a finding that supports the notion that it is acceptable 
to delay a more aggressive treatment alternative for a few months in favor of methotrexate 
monotherapy. This finding has been supported by data from the recent TEAR trial including poor 
prognosis early RA, as well as previous reports from the Swefot study, where patients who had a 
favorable response to methotrexate monotherapy within 6 months continued to do well both clinically 
and radiographically.110,120 However, no analysis using work loss as an outcome has been reported 
from the TEAR trial. 
With an immediate aggressive combination therapy, rather than a step-up treatment strategy, the risk 
of over-treating in the approximately one third of patients with early RA who respond to the initial 
methotrexate therapy would be reduced, with reduced risks of adverse consequences. However, 
immediate initiation of aggressive therapy may be warranted in some patients, and predictors of 
achieving EULAR good response at the time of initiation with methotrexate monotherapy has 
previously been investigated in the participants of the Swefot trial.121 
5.4 STRENGTHS 
In this population-based matched cohort study design, detailed clinical data from the SRQ was used 
as a foundation, with patients enrolled in the randomized Swefot trial included, and were linked to 
nationwide register data. This design enabled follow-up of patients with RA alongside general 
population comparators, both backward and forward in time from the date of RA diagnosis, and date 
of randomization for patients in the Swefot trial. The matched comparators served as a benchmark of 
mean annual cost of health care, drugs, and productivity losses (paper II; Figure 7 and 8), as well as a 
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benchmark for mean monthly days of sick leave and disability pension (paper III; Figure 9) in the 
general population as compared to newly diagnosed patients with RA. Thus, the overall cost, including 
loss of work days, associated with the RA disease could be estimated. 
Non-response and recall bias, associated with questionnaires, were avoided by access to nationwide 
health care data from inpatient and non-primary outpatient care, prescription drugs, and objectively 
assessed sick leave and disability pension. All these data were on an individual level and on a daily 
basis, and were available for all study subjects, including those patients who discontinued the Swefot 
trial, as well as for general population comparators. The use of national data sources also resulted in 
a large sample size of incident patients, with the possibility of robust subgroup estimates and of testing 
different case definitions of register-based incident RA. The methodology used in the incidence study 
of RA (paper I), as in register-based methodology in general, is relatively easy to reproduce with the 
same setting and may be used in time-trend analysis in future data linkages. Moreover, the detailed 
clinical data of quality of life from the SRQ combined with cost components captured from national 
registers, enabled, to the best of our knowledge, the first cost-effectiveness analysis of a register-
enriched randomized controlled trial (paper IV). 
Finally, with respect to the register-based methodology, the data linkage procedure used in this thesis 
maximizes data use from national health register sources routinely collected in clinical care and from 
drug prescriptions given in ambulatory care, while the clinical variables entered into the SRQ can be 
minimized, an important feature to lower the work load for rheumatologists entering data into SRQ. 
5.5 LIMITATIONS 
The register-based approach also has limitations. One limitation with a register-based study design is 
that identification of subjects may be sensitive to the case definition of disease based on clinical 
criteria, such as RA. To qualify as having RA in the SRQ the ACR criteria54 are used at inclusion, while 
this may not be the case for patients listing a diagnosis of RA in the National Patient Register with visits 
at non-rheumatology departments. In the study of RA incidence (paper I) we assessed the risk of 
misclassification by testing the sensitivity of the register-identification of incident RA and estimated 
the treatment penetration in the identified RA cases, given that close to all patients in Sweden with 
new onset RA are initiating DMARD therapy. Furthermore, a validation study of the RA diagnosis in 
the National Patient Register showed a high validity, with 90% of prevalent RA fulfilled either of the 
ACR or the ACR/EULAR classification criteria.84 
Another limitation is that using a register-based approach may introduce selection bias due to missing 
individuals who have problems with accessing care, for example older people and people with severe 
diseases. This may potentially result in an underestimation of the true number of individuals with RA. 
From the registers we did not have access to all possible cost components, for example costs related 
to primary care, physiotherapist visits, stays in rehabilitation units, transportation, presenteeism, 
unpaid work, and out-of-pocket patient and family costs. With the absence of these cost components 
the true cost was probably underestimated. A recent review estimated cost associated with patient 
and family to €2284, which was 18% of the total societal cost based on pooled health care costs and 
productivity losses from different cost of illness studies, and where productivity losses was valued with 
the human capital approach.104 A recent study from Norway reported costs associated with visits to 
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primary care and physiotherapists, and stays in rehabilitation units in patients with RA, who had 
initiated first-line DMARD therapy, to compose 4.1% of the total cost.122 However, while the total 
societal costs in prevalent and incident RA are likely to be underestimated in our study (paper II), we 
had access to the major cost components, i.e. health care use, drugs, and productivity losses. 
Moreover, with the similar improvement in quality of life between the infliximab versus the 
conventional combination therapy, and the large drug cost difference, it would be unlikely that any 
potential cost differences in missing cost components would change the study conclusion of the cost-
effectiveness analysis. 
A further limitation was that we did not have access to sick leave periods shorter than 15 days, which 
is the time period that was covered by the employer during the study period (except the unpaid 1st 
day of sick leave). Given the chronic inflammatory and destructive nature of the RA disease, sick leave 
periods for RA are usually not short. In a study from Finland, with a similar social security system as 
compared to Sweden, sick leave periods of 10 days or less were found to constitute only 0.2% of total 
sick leave days in recent onset RA during 5 years of follow-up.106 This finding indicates that the 
potential underestimation of sick leave days due to missing short sick leave periods in our data may 
be limited. 
The unblinded design is probably the most important concern with the Swefot trial, i.e. both patients 
and physicians were aware of the treatment allocation. Single-blinding of the trial was considered, 
which would be blinding of the treatment allocation when assessing disease activity, but was deemed 
unfeasible due to limited personnel resources at smaller participating units. However, the work loss 
outcome (paper III) and cost outcomes (paper IV) were objectively assessed using registers, and the 
radiological results were assessed by readers masked to the allocated treatment. 
With the unblinded design it is not unreasonable to believe that patients allocated to conventional 
treatment may have been more willing to abandon the allocated therapy for perceived lack of 
effectiveness, while patients allocated to TNFi therapy may have continued with the regimen knowing 
that no superior alternative was available. However, findings from the one-year data argue against 
this hypothesis,65 with indeed high disease activity, and at a similar level at the time of discontinuation 
between the two groups of those who discontinued the allocated treatment. 
Other limitations of the work loss (paper III) and the cost-effectiveness (paper IV) studies based on 
data from the Swefot trial were the short time horizon and the limited number of included study 
subjects. Rather than diverging, however, the average monthly days of work loss followed a similar 
trajectory between the infliximab and the conventional combination strategy over 21 months. With 
no difference in disease activity over 2 years,66 and with a similar trajectory in health related quality of 
life,92 it is difficult to consider that the two strategies may start to diverge in the future owing to the 
small difference in radiographic progression. Data on work loss and health care use will be possible to 
analyze over longer time horizons, as these outcomes are collected via register-linkage. 
With 204 working age patients included in the work loss study (paper III), 258 randomized individuals 
in the cost-effectiveness analysis (paper IV), and a power analysis in the study-design phase based on 
disease activity measured after 1 year and not based on work loss days, costs, or QALYs after 21 
months, there may be a risk of type II error. From Figure 5 it can be concluded that more than 500 
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patients per group would be needed to detect a difference in mean lost work days of 1.6 days/month 
to a power of 75%. An RCT including more than 1000 patients, even enrolling patients included in the 
SRQ, would be expensive and rather unrealistic to conduct. This together with the possibly unexpected 
result of a non-significant point estimate (1.6 days/month) not favoring the infliximab treatment 
indicate that the potential problem with a type II error for detecting a statistical difference may not be 
a major concern for the conclusion of the study. Again, the quality of life and work loss development 
showed similar trajectories between the treatment strategies over 21 months of follow-up, while the 
drug cost was considerably higher in the infliximab arm. 
5.6 CONCLUSIONS 
Register-enriched quality of care register data in Sweden can be used to study nationwide real-life 
occurrence and burden of disease with the possibilities of robust subgroup estimates and time-trend 
analysis by establishing a database that is easy to reproduce and update within the same setting. 
By using the SRQ linked to national registers we could estimate the overall incidence of RA in Sweden 
on a par with previous local but detailed studies, and importantly, beyond estimates across age and 
sex, describe the variation in age- and sex adjusted incidence according to region, population density, 
and level of education. With general population comparators individually matched to register-
identified subjects with RA we could also estimate the annual societal cost in prevalent as well as 
monthly societal cost in newly diagnosed patients with RA to 2-3 times higher relative to the general 
population. With the individual level data we could further describe the cost distribution. The 
distribution was found to be heavily right-skewed, with a minority of the patients with RA contributed 
the majority of the total cost. This emphasizes the notion that predicting and intervening for reducing 
costs in RA may be very different in different patients segments. 
The register-enriched quality of care register data with the observational nature is by itself an 
important and highly useful database with possibilities to answer an abundance of research questions 
by using many different outcomes over long time periods and in a real-world setting. However, the 
true potential is when combining such a framework with a pragmatic randomized controlled trial 
included in the quality register platform. 
The randomized Swefot trial investigated a common clinical situation in early RA, whether to intensify 
treatment by adding an expensive biologic drug or further conventional DMARDs to patients with 
insufficient response to methotrexate. Data from enrolled patients were collected in the SRQ, and thus 
allowed for investigating this research question using different outcomes in a register-enriched 
randomized controlled trial setting. 
With respect to work loss, the decrease in mean monthly work loss days was substantial in both 
treatment alternatives, with a reduction of 3 times to double that in the general population from 
randomization to 21 months of follow-up, but no difference between the strategies could be detected 
at 12 or 21 months after randomization. The remaining gap to the general population indicates a need 
for earlier diagnosis as well as for more effective treatment strategies of RA. 
Finally, by combining quality of life data from the randomized Swefot trial with costs captured from 
the national registers, similar effects were observed over 21 months, while the infliximab strategy 
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incurred higher costs, as compared to the conventional treatment. These findings indicate that the 
infliximab strategy is not cost-effective as second line treatment at willingness-to-pay levels generally 
considered acceptable. 
5.7 FUTURE RESEARCH 
The register-based methodology used in this thesis is an effective approach to research that can be 
conducted to a relatively low cost, and is comparatively easy to replicate in other disease areas. With 
the many quality of care registers in Sweden that collect data on different diseases and interventions, 
there is great potential for conducting effective research using similar study designs. 
Since the introduction of biologic drugs the research field of RA has attracted more attention and is 
today an intense and highly active field of medical research. However, many research questions still 
remain unanswered. In relation to the studies in this thesis the following questions would be of 
interest 
 Incidence of RA: 
To understand how future estimates from similar register-based designs with similar register-
identification definitions relate to changes in the classification criteria of RA. 
 
 Need for earlier diagnosis of RA: 
To identify patients earlier in the disease course of RA may have the potential of improving 
patients’s clinical outcomes as well as reducing sick leave and disability pension days due to 
RA. 
 
 Treatment in early RA: 
The overall question is which therapy to initiate in whom, and which therapy to continue with, 
and in whom, of those not responding to the first-line treatment. That is, how can therapy 
need be predicted on an individual level? 
 
 Long-term follow-up of register-based outcomes in the Swefot trial: 
The radiologically superior outcomes in the infliximab strategy, as compared to the triple 
therapy strategy, after methotrexate failure may have an effect in the longer term. With the 
work loss and cost data collected from registers, these outcomes could be investigated over 
several years by an update of the register linkage with more recent data. 
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inspiration genom att vara ett bra exempel på att godhet och generositet genom livet lönar sig i 
längden. Tack Laila för att du finns! 
Till sist, till Camilla. Du är mitt eget solsken som förgyller mitt liv med värme och glädje. 
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8 SAMMANFATTNING PÅ SVENSKA 
8.1 BAKGRUND 
8.1.1 Registerforskning i Sverige 
Svenska register har i decennier och med framgång använts för medicinsk forskning. I Sverige är 
registerbaserad forskning möjlig dels genom att vårdsystemet är skattefinansierat och tillgängligt för 
alla medborgare, dels genom ett personnummerbaserat registersystem av hälsodata. Med hjälp av 
personnummer registreras information om till exempel dödsorsaker, cancer, utskrivna 
receptläkemedel, samt sjukvårdsbesök vid både öppenvårdskliniker och inläggningar i slutenvård. Från 
dessa hälsoregister kan information inhämtas för olika exponeringar med avseende på utskrivna 
receptläkemedel och sjukdomstillstånd, liksom utfall som död, cancer, eller något annat 
sjukdomstillstånd som kräver sjukhusvård. 
Utöver nationella hälsoregister har även kliniska kvalitetsregister för specifika diagnoser och 
interventioner etablerats, där data insamlas i klinikens dagliga verksamhet. Syftet med 
kvalitetsregister är att följa upp och förbättra vården, i vissa fall bidra med beslutsstöd till den 
ansvariga läkaren, och att bedriva forskning. De första kvalitetsregistren startade redan på 70-talet 
med knäplastikregistret och höftplastikregistret, och därefter har fler och fler kvalitetsregister startats. 
År 2014 fanns 81 olika kvalitetsregister med varierande kvalitetsgrad certifierade i Sverige. 
Svensk reumatologis kvalitetsregister (SRQ) startade i mitten av 90-talet med det primära syftet att 
förbättra vård och behandling av patienter med reumatoid artrit (RA), men började senare också att 
inkludera patienter med andra reumatiska sjukdomar. I slutet av 90-talet, när de första biologiska 
läkemedlen för RA blev godkända i Sverige, startades det biologiska behandlingsregistret ARTIS som 
en del av SRQ. 
8.1.2 Reumatoid artrit (RA) 
RA, även kallad ledgångsreumatism, är den vanligast förekommande kroniskt inflammatoriska 
ledsjukdomen. Ungefär 0.7% av Sveriges vuxna befolkning (ca 50,000 personer) lever med diagnosen 
RA, med större förekomst hos kvinnor än hos män och ökad förekomst med ökad ålder. Den mest 
betydelsefulla faktorn för RA-sjukdomens utveckling hos drabbade personer är behandling. Sedan 
introduktionen av biologiska preparat i slutet av 90-talet har behandling av RA förändrats radikalt, men 
till en betydligt högre kostnad än tidigare tillgängliga behandlingsalternativ. De biologiska läkemedlen 
påverkar immunsystemet och har visat sig vara mer effektiva än konventionell standardbehandling för 
reducering av sjukdomsaktivitet och minskad radiologisk förändring (strukturella förändringar i leder), 
men är associerade med vissa biverkningar. 
Till följd av den stora utbredningen av RA och till följd av det lidande som RA medför är 
samhällskostnaderna stora. Effektivare behandling i form av biologiska läkemedel har givit 
förhoppningar om att produktionsbortfall i form av sjukskrivning och förtidspension, som utgör den 
största delen av den totala kostnaden för samhället, minskas i högre utsträckning och på så sätt 
ekonomiskt försvara dessa läkemedel. 
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8.1.3 Swefot – en randomiserad kontrollerad studie 
Syftet med Swefot-studien var att jämföra intensiva behandlingsalternativ av konventionell 
kombinationsbehandling, även kallad trippelterapi, med det biologiska läkemedlet infliximab plus 
metotrexat. Dessa behandlingsalternativ prövades av patienter med nydebuterad RA som inte svarade 
på enbart standardbehandlingen metotrexat. Studien genomfördes på 15 olika 
reumatologmottagningar runt om i Sverige och rekryterade patienter med nydebuterad RA fick 
metotrexat under tre månader. Patienter som inte svarade på metotrexat randomiserades till 
infliximab plus metotrexat eller till trippelterapi. Resultat med avseende på sjukdomsaktivitet efter ett 
år visade att patienter i infliximabgruppen svarade i högre utsträckning på behandlingen jämfört med 
patienter i trippelterapigruppen. Efter två år kunde dock inte någon skillnad i sjukdomsaktivitet 
påvisas. Däremot hade patienterna i infliximabgruppen en lägre förekomst av radiologiska 
förändringar efter två år. 
8.2 SYFTE 
Syftet med denna avhandling var att beskriva hur svensk registerdata kan användas vid 
epidemiologiska frågeställningar och vid utvärdering av sjukvård genom att använda SRQ länkat till 
nationella register och register vid Försäkringskassan. Det specifika syftet med de enskilda studierna 
var att 
1. Beräkna incidensen (nyinsjuknandet) av RA i Sverige totalt, samt uppdelat på kön, ålder, 
utbildningsnivå, och hemvist (studie I) 
2. Beräkna sjukdomsbördan av RA med avseende på kostnad för sjukvård, läkemedel, och 
produktionsbortfall i relation till allmänbefolkningen (studie II) 
3. Beräkna effekten på sjukskrivning och förtidspension av biologisk behandling med infliximab 
jämfört med konventionell kombinationsbehandling bland patienter med nydebuterad RA 
(studie III) 
4. Genomföra en kostnadseffektivitetsanalys av infliximab jämfört med konventionell 
kombinationsbehandling (studie IV) 
8.3 METOD 
Genom att använda personnummer har vi länkat ihop SRQ och nationella hälsoregister, samt även 
information om sjukskrivning och förtidspension (sjukersättning/aktivitetsersättning) från 
Försäkringskassan. Till en relativt låg kostnad skapades därigenom en kraftfull forskningsdatabas. Med 
klinisk detaljerad data från SRQ tillsammans med observationella data av lång och praktiskt taget 
fullständig uppföljning från framförallt klinisk daglig verksamhet samt data på utskrivna 
receptläkemedel, men också uppgifter om arbetsoförmåga, kan flera olika frågeställningar i ett stort 
urval av patienter med RA studeras. I databasen ingår även fem jämförelseindivider från 
allmänbefolkningen utan RA som har matchats per RA-patient på ålder, kön, utbildningslängd, 
bostadslän, och år. 
I tillägg har data från den randomiserade studien Swefot registrerats i SRQ. Tillsammans med de 
fördelar som observationella data ger av lång och nära nog komplett uppföljning av många olika och 
objektivt bedömda utfall, kunde vi bland randomiserade patienter jämföra hälsoekonomiska utfall 
som arbetsoförmåga och kostnadseffektivitet. Den randomiserade designen resulterar i en minskad 
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risk av att andra faktorer påverkar behandlingen och utfallet (confounders), vilket kan leda till felaktiga 
resultat. 
8.4 RESULTAT 
8.4.1 Studie I – Incidens av RA 
Med en registerbaserad definition identifierades 8826 individer som nyinsjuknade i RA under 2006-
2008 i Sverige, vilket motsvarar en incidens av 41 per 100,000 individer. Incidensen var 56 per 100,000 
för kvinnor och 25 per 100,000 för män, och ökade med ålder till 70-79 år bland både kvinnor och män 
(Figur 6). Vidare noterade vi en lägre incidens av RA i tätbefolkade områden och bland personer med 
högre utbildning, men ingen geografisk trend kunde urskiljas. Genom att ändra vår identifierings-
algoritm testade vi den registerbaserade definitionen av nydebuterad RA till en mer strikt och mer 
liberal definition, vilket resulterade i att det totala incidensestimatet ändrades med mindre än 15%. 
8.4.2 Studie II – Kostnader för sjukvård, läkemedel och arbetsoförmåga bland 
patienter med RA 
Medelkostnaden per patient med RA i arbetsför ålder uppgick till €23,000 per år, av vilket en fjärdedel 
var sjukvårdskostnader och tre fjärdedelar utgjorde produktionsförluster (Figur 7). Bland pensionärer 
med RA var medelkostnaden per patient €4000 per år, med slutenvård som den största kostnaden. 
Jämfört med allmänbefolkningen var dessa kostnader 2-3 gånger större, medan medelkostnaden 
bland patienter med RA som använder biologiska läkemedel var 4 gånger större i den arbetsföra 
åldern, och 6-7 gånger större bland pensionärer. 
Jämfört med allmänbefolkningen, ökade medelkostnaderna per patient med nydebuterad RA från 
samma nivå 12 månader före diagnos, toppade med 3 gånger kostnaden månaden efter diagnos, för 
att minska till den dubbla kostnaden jämfört med allmänbefolkningen 12 månader därefter (Figur 8). 
8.4.3 Studie III – Infliximab jämfört med konventionell kombinationsbehandling och 
arbetsoförmåga bland patienter med nydebuterad RA 
Patienter med nydebuterad RA som inte svarade på sin initiala metotrexatbehandling randomiserades 
till att behandlas med infliximab eller med konventionell kombinationsterapi i tillägg till metotrexat. 
Båda behandlingsgrupperna minskade avsevärt antal medeldagar per månad av sjukskrivning och 
förtidspension under 21 månaders uppföljning, men ingen skillnad mellan behandlingsgrupperna 
kunde påvisas.  
Vid 12 månader före randomisering ökade antal medeldagar per patient från samma nivå som 
allmänbefolkningen, för att vara som högst vid månaden före randomisering med 17 dagar i båda 
grupperna, vilket var 3 gånger så mycket som allmänbefolkningen. Vid 21 månader efter 
randomisering hade antal medeldagar per månad reducerats till den dubbla jämfört med 
allmänbefolkningen (Figur 9). 
Patienter som inte randomiserats, av vilka de allra flesta hade ett tillräckligt bra svar på sin initiala 
metotrexatbehandling, startade från färre dagar av sjukskrivning och förtidspension jämfört med de 
randomiserade patienterna och minskade antal medeldagar per månad till samma nivå som 
allmänbefolkningen inom 1 år efter behandlingsstart (Figur 9). 
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8.4.4 Studie IV – Kostnadseffektivitet av infliximab jämfört med konventionell 
kombinationsbehandling bland patienter med nydebuterad RA 
Under 21 månader observerade vi högre läkemedel och sjukvårdskostnader bland patienter med 
nydebuterad RA som slumpmässigt tilldelats behandling med infliximab, jämfört med de patienter 
som slumpmässigt tilldelats behandling med konventionell kombinationsterapi efter ett otillräckligt 
svar av metotrexatbehandling. Däremot kunde ej någon skillnad i hälsorelaterad livskvalitet med 
kvalitetsjusterade levnadsår (QALY) påvisas. Den ökade kostnaden per QALY för behandlingsstrategin 
med infliximab jämfört med konventionell kombinationsterapi blev därför mycket hög, med €2,4 
miljoner per QALY från ett samhällsperspektiv (inklusive produktionsbortfall) och €1,9 miljoner per 
QALY från ett sjukvårdsperspektiv (exklusive produktionsbortfall). Dessa kostnader per QALY är högre 
än vad som vanligtvis anses vara acceptabla nivåer för kostnadseffektivitet. 
8.5 SLUTSATS 
Registerberikade kvalitetsregister kan användas för att på nationell nivå studera sjukdomsförekomst 
och sjukdomsbörda med goda möjligheter till subgrupps- och tidsserieanalyser. Detta är möjligt 
genom att tillfälligt upprätta en forskningsdatabas som är relativt lätt att återskapa med uppdaterad 
data. 
Genom att data från den randomiserade Swefot-studien registrerades i SRQ, kunde vi i en 
registerberikad randomiserad studie undersöka hälsoekonomiska utfall i en klinisk vanlig 
behandlingssituation för patienter med nydebuterad RA, nämligen huruvida fortsatt behandling med 
ett biologiskt läkemedel (infliximab) är bättre än fortsatt behandling med konventionella läkemedel 
bland patienter som misslyckats med en initial metotrexatbehandling. 
Båda behandlingsgrupperna i Swefot-studien minskade väsentligt antal medeldagar av sjukskrivning 
och förtidspension under 21 månader, men ingen skillnad mellan grupperna kunde påvisas. Antal 
dagar vid 21 månader efter randomisering var fortfarande det dubbla jämfört med 
allmänbefolkningen, vilket indikerar ett behov av effektivare behandlingsalternativ och att tidigare 
kunna diagnostisera nydebuterad RA. 
Slutligen, genom att kombinera data av livskvalitet från den randomiserade Swefot-studien med 
kostnader inhämtade från nationella register observerades under 21 månader en liknande utveckling 
av behandlingseffekt mellan infliximab och trippelterapigruppen, medan patienter i infliximabgruppen 
ackumulerade betydligt högre kostnader. En mindre radiologisk progress observerades dock bland 
patienter i behandlingsstrategin med infliximab, vilket innebär att framtida studier med längre 
uppföljning eventuellt behöver bekräfta dessa studieresultat. 
